Akili (AKLI) 10-K 29 Feb 24 2023 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Feb. 21, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Registrant Name	Akili, Inc.
Entity Central Index Key	0001850266
Entity File Number	001-40558
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Tax Identification Number	92-3654772
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	71 Commercial Street
Entity Address, Address Line Two	Mailbox 312
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02109
City Area Code	617
Local Phone Number	313-8853
Document Annual Report	true
Document Transition Report	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Title of 12(b) Security	Common stock, $0.0001 par value per share
Trading Symbol	AKLI
Security Exchange Name	NASDAQ
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Common Stock, Shares Outstanding		78,509,823
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023 are incorporated herein by reference in Part III of this Annual Report on Form 10-K.
Entity Public Float			$ 66,983,433
Auditor Firm ID	185
Auditor Location	Boston, Massachusetts
Auditor Name	KPMG LLP

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 75,150	$ 54,097
Restricted cash	305	305
Short-term investments		82,034
Accounts receivable	300	41
Prepaid expenses and other current assets	2,275	4,565
Total current assets	78,030	141,042
Property and equipment, net	680	919
Operating lease right-of-use asset	1,577	2,596
Prepaid expenses and other long-term assets	96
Total assets	80,383	144,557
Current liabilities:
Accounts payable	1,285	2,681
Accrued expenses and other current liabilities	3,326	5,616
Deferred revenue	100	106
Operating lease liability	756	826
Note payable, short term	7,500	4,375
Total current liabilities	12,967	13,604
Note payable, long term	3,445	10,442
Operating lease liability, net of current portion	1,730	2,485
Corporate bond, net of bond discount	2,054	1,834
Earn-out liabilities	1,632	5,513
Other long-term liabilities	23
Total liabilities	21,851	33,878
Commitments and contingencies
Stockholders' equity
Common stock, $0.0001 par value: 1,000,000,000 shares authorized; 78,356,527 and 78,022,924 shares issued and outstanding at December 31, 2023 and 2022, respectively	8	8
Additional paid-in capital	358,305	350,980
Accumulated deficit	(299,781)	(240,288)
Accumulated other comprehensive loss		(21)
Total stockholders' equity	58,532	110,679
Total liabilities and stockholders' equity	$ 80,383	$ 144,557

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	78,356,527	78,022,924
Common stock, shares outstanding	78,356,527	78,022,924

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 1,678	$ 323
Cost of revenues	819	441
Gross profit (loss)	859	(118)
Operating expenses:
Research and development	19,925	28,858
Selling, general and administrative	45,419	61,701
Total operating expenses	65,344	90,559
Operating loss	(64,485)	(90,677)
Other income (expense):
Other income	4,040	1,482
Interest expense	(2,358)	(1,484)
Change in estimated fair value of earn-out liabilities	3,363	82,734
Total other income	5,045	82,732
Loss before income taxes	(59,440)	(7,945)
Income tax expense	(53)	(19)
Net loss	(59,493)	(7,964)
Unrealized gain (loss) on short-term investments	21	(21)
Comprehensive loss	(59,472)	(7,985)
Net loss	(59,493)	(7,964)
Dividends on Series D convertible preferred stock		(7,383)
Redemption value of Series D convertible preferred stock	0	(3,692)
Net loss attributable to common stockholders - basic	$ (59,493)	$ (19,039)
Net loss per share attributable to common stockholders - basic	$ (0.76)	$ (0.64)
Net loss per share attributable to common stockholders - diluted	$ (0.76)	$ (0.64)
Weighted average common stock outstanding - basic	78,197,107	29,878,041
Weighted average common shares outstanding - diluted	78,197,107	29,878,041

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (unaudited) - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning Balance at Dec. 31, 2021	$ (226,114)				$ (226,114)
Temporary Equity, Beginning Balance, Shares at Dec. 31, 2021		43,318,218
Temporary Equity, Beginning Balance at Dec. 31, 2021		$ 291,876
Beginning Balance, Shares at Dec. 31, 2021			1,674,106
Stock-based compensation expense	8,574			$ 8,574
Exercise of stock options	149			149
Exercise of stock options, Shares			116,299
Stock dividend accrued for Series D preferred stock	(7,383)			(4,865)	(2,518)
Stock dividend accrued for Series D preferred stock, Temporary Equity		$ 7,383
Stock dividend accrued for Series D preferred stock, Shares, Temporary Equity		1,008,596
Redemption value of Series D preferred stock	(3,692)				(3,692)
Redemption value of Series D preferred stock, Temporary Equity		$ 3,692
Redemption value of Series D preferred stock, Shares, Temporary Equity		8,472,752
Exercise of Legacy Akili warrants			8,834
Vesting of common stock warrants	282			282
Conversion of redeemable preferred stock into common stock, Temporary Equity		$ (302,951)
Conversion of redeemable preferred stock into common stock, Shares, Temporary Equity		(52,799,566)
Conversion of redeemable preferred stock into common stock	302,951		$ 5	302,946
Conversion of redeemable preferred stock into common stock, Shares			52,799,566
Issuance of common stock related to Business Combination and PIPE Investment	164,283		$ 3	164,280
Issuance of common stock related to Business Combination and PIPE Investment, Shares			23,367,500
Reverse recapitalization, net of transaction costs (including ($87,512) of deemed dividends related to Earn-Out Shareholders)	(120,386)			(120,386)
Vesting of RSUs			56,619
Other comprehensive income (loss)	(21)					$ (21)
Net loss	(7,964)				(7,964)
Ending Balance at Dec. 31, 2022	110,679		$ 8	350,980	(240,288)	(21)
Ending Balance, Shares at Dec. 31, 2022			78,022,924
Stock-based compensation expense	$ 7,325			7,325
Exercise of stock options, Shares	28,778		28,224
Vesting of RSUs			305,379
Other comprehensive income (loss)	$ 21					$ 21
Net loss	(59,493)				(59,493)
Ending Balance at Dec. 31, 2023	$ 58,532		$ 8	$ 358,305	$ (299,781)
Temporary Equity, Ending Balance, Shares at Dec. 31, 2023	0
Ending Balance, Shares at Dec. 31, 2023			78,356,527

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) (unaudited) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Earn-Out Shareholders
Deemed dividends	$ 87,512

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (59,493)	$ (7,964)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	302	308
Reduction in the carrying amount of right-of-use assets	692	489
Impairment loss on sublease	385
Stock-based compensation expense	6,807	9,309
Loss on disposal of fixed assets	22
Amortization of premium on short-term investments	(1,501)	(881)
Non Cash Interest Expense	723	512
Change in fair value of earn-out liabilities	(3,363)	(82,734)
Changes in operating assets and liabilities:
Accounts receivable	(259)	(12)
Prepaid expenses and other current assets	2,408	(2,037)
Prepaid expenses and other long-term assets	(96)	11
Accounts payable	(1,396)	387
Accrued expenses and other current liabilities	(2,290)	(310)
Other long term liabilities	23	(24)
Operating lease liabilities	(825)	(585)
Deferred revenue	(6)	10
Net cash used in operating activities	(57,867)	(83,521)
Cash flows from investing activities:
Acquisition of property and equipment	(19)	(42)
Capitalized software development costs	(124)
Purchases of short-term investments	(56,444)	(111,174)
Proceeds from maturities of short-term investments	140,000	30,000
Net cash provided by (used in) investing activities	83,413	(81,216)
Cash flows from financing activities:
Proceeds from exercise of stock options		149
Proceeds from note payable		10,000
Proceeds from business combination net of transaction costs paid		131,814
Taxes paid related to net share settlement of share-based awards	(118)	(28)
Repayment of principal on note payable	(4,375)
Net cash provided by (used in) financing activities	(4,493)	141,935
Net increase (decrease) in cash, cash equivalents, and restricted cash	21,053	(22,802)
Cash, cash equivalents, and restricted cash at beginning of period	54,402	77,204
Cash, cash equivalents, and restricted cash at end of period	75,455	54,402
Supplementary Information:
Cash paid for income taxes	16
Cash paid for interest	$ 1,665	834
Noncash investing and financing activities:
Deferred asset for fees related to undrawn debt included in accrued expenses		51
Common stock warrants issued related to note payable		282
Redemption value of Series D preferred stock		3,692
Dividends accrued for Series D preferred stock		7,383
Recognition of liabilities for Earn-Out Shareholders		87,512
Net liabilities assumed in the business combination		$ 500

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Busin ess and Basis of Presentation Organization Akili, Inc. (collectively referred to with its wholly-owned, controlled subsidiaries, as “Akili” or the “Company”) operates as one business segment and is a leading digital medicine company, pioneering the development of cognitive treatments through game-changing technologies. Akili’s approach of developing and commercializing technologies designed to directly target the physiology of the brain has established a new category of medicine—medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. In June 2020, EndeavorRx, the first product built on Akili’s platform, was granted marketing authorization and classified as a Class II medical device by the U.S. Food and Drug Administration (“FDA”) through FDA’s de novo process. EndeavorRx is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue, following the Company’s receipt of FDA authorization in December 2023 for the expanded EndeavorRx label to include older children ages 13-17. In June 2023, the Company released EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined-type ADHD, under the FDA guidance entitled “ Enforcement Policy for Digital Health Devices for Treating Psychiatric Disorders During the Coronavirus Disease 2019 Public Health Emergency ” (the “COVID-19 Guidance”). The COVID-19 Guidance allows for the marketing of certain digital therapeutics without premarket clearance, de novo classification, or approval so long as certain criteria are met for the duration of the COVID-19 Guidance, which was expected to remain in effect until November 7, 2023 consistent with FDA guidance entitled “ Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency ” (the “COVID-19 Transition Guidance”). The COVID-19 Transition Guidance allows for the continued distribution of devices falling under the COVID-19 Guidance without marketing authorization so long as the manufacturer has submitted a marketing submission to FDA, the submission has been accepted by FDA prior to November 7, 2023 and FDA has not taken a final action on the marketing submission. While EndeavorOTC has not been authorized by FDA for any indications, the Company submitted a marketing submission to FDA for EndeavorOTC on October 30, 2023. Through guidance from FDA regarding the COVID-19 Transition Guidance, it was clarified that marketing submissions received by FDA on or before November 7, 2023, that pass their technical review after the deadline without being placed on submission hold will still be eligible for continued enforcement discretion. Pursuant to FDA’s guidance on this topic, and given that the Company has since passed FDA’s technical review and has not been placed on submission hold, the Company is continuing to commercialize, distribute, and market EndeavorOTC under the COVID-19 Guidance. The Company’s efforts are primarily focused on managing and executing its strategic plan to transition from a prescription to a non-prescription model, including obtaining regulatory authorization and commercializing EndeavorOTC in adults with ADHD, pursuing regulatory authorization for over-the-counter labeling of both its EndeavorRx and EndeavorOTC products and continuing to support the distribution and fulfillment of EndeavorRx during the transition. Further development of Akili’s programs outside of ADHD will be contingent upon a number of factors, including capital raising and supportive business development activities. The Company is headquartered in Boston, Massachusetts. On August 19, 2022, (the “Closing Date”), Social Capital Suvretta Holdings Corp. I (“SCS”) consummated the previously announced merger pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated January 26, 2022, by and among SCS, Akili Interactive Labs, Inc. and Karibu Merger Sub, Inc., pursuant to which Karibu Merger Sub, Inc. merged with and into Akili Interactive Labs, Inc., with Akili Interactive Labs, Inc. becoming a wholly owned subsidiary of SCS (the “Business Combination”). Upon the closing of the Business Combination (the “Closing”), SCS changed its name to Akili, Inc. In connection with the Business Combination, SCS completed the sale and issuance of 16,200,000 shares of Akili, Inc. common stock, $ 0.0001 par value per share (the “Common Stock”) in a private placement transaction for a purchase price of $ 10.00 per share for $ 162,000 in the aggregate (the “PIPE Investment”). Gross proceeds from the Merger totaled approximately $ 164,283 which included funds held in SCS’s trust account (after giving effect to redemptions). In connection with the Business Combination, approximately $ 31,438 of transaction costs and other fees were incurred. References to SCS refer to the Company prior to the consummation of the Business Combination and references to “Legacy Akili” refer to Akili Interactive Labs, Inc. (now a wholly-owned subsidiary of Akili, Inc.) prior to the consummation of the Business Combination. Legacy Akili was deemed the accounting acquirer in the Business Combination. This determination was primarily based on Legacy Akili’s stockholders prior to the Business Combination having a majority of the voting power in the combined company, Legacy Akili having the ability to appoint a majority of the board of directors of the combined company (the “Board”), Legacy Akili’s existing management comprising the senior management of the combined company, Legacy Akili comprising the ongoing operations of the combined company, Legacy Akili being the larger entity based on historical revenues and business operations, and the combined company assuming Legacy Akili’s name. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy Akili issuing stock for the net assets of SCS, accompanied by a recapitalization. Under this method of accounting, SCS who was the legal acquirer, is treated as the “acquired” company for financial reporting purposes. The net assets of SCS are stated at historical cost, with no goodwill or other intangible assets recorded. The equity structure has been restated in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s Common Stock, $ 0.0001 par value per share, issued to Legacy Akili stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Akili’s convertible preferred stock (“Legacy Convertible Preferred Stock”) and Legacy Akili common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of approximately 1.15 pursuant to the terms of the Business Combination. Legacy Convertible Preferred Stock previously classified as mezzanine was retroactively adjusted, converted into Common Stock, and reclassified to permanent as a result of the reverse recapitalization. Akili, Inc. (formerly SCS) is a Delaware corporation incorporated on December 1, 2020. Akili Interactive Labs, Inc. is a Delaware corporation incorporated on December 1, 2011. Going Concern The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. The Company requires a significant amount of capital to fund its current operating requirements as it pursues its strategic goals. The Company’s efforts are primarily focused on managing and executing its strategic plan to transition from a prescription to a non-prescription model, including obtaining regulatory authorization and commercializing EndeavorOTC for the adult ADHD market, pursuing regulatory authorization for over-the-counter labeling of both its EndeavorRx and EndeavorOTC products and continuing to support the distribution and fulfillment of EndeavorRx during the transition. There can be no assurance that the Company’s product development and commercialization efforts will be successful; that adequate protection for the Company’s intellectual property will be obtained; that any products developed will obtain necessary government regulatory authorization; or that any products will be commercially viable. Even if the Company’s product development and commercialization efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants. The Company’s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has experienced negative operating cash flows for the year ended December 31, 2023 and had an accumulated deficit of $ 299,781 at December 31, 2023. The Company believes that its cash and cash equivalents at December 31, 2023 of $ 75,150 will be sufficient to fund the Company’s planned operations and existing obligations for at least one year after the date that the consolidated financial statements are issued. The future viability of the Company is dependent on its ability to generate cash from operating activities, manage liquidity by maintaining reduced operating expenses or to raise additional capital to finance its operations. The Company’s failure to generate cash from operating activities or to raise capital when needed, or on terms favorable to the Company, could have a negative impact on its financial condition and ability to pursue its business strategies. Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company, after elimination of all intercompany accounts and transactions.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of the earn-out liability and the valuation of stock-based awards. On an ongoing basis, management evaluates its estimates, including those related to accrued liabilities and stock-based compensation expense. Actual results could differ from the Company’s estimates. Cash and cash equivalents: The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market accounts, are stated at fair value. Restricted cash: Restricted cash consists of two savings accounts. One is required as collateral for the business credit cards which remains restricted until the contract is terminated and the obligation is paid in full. The second is a security deposit for an office lease in Larkspur, California and remains in place until the lease ends in 2026. Investments: The Company considers all investments with original maturities of more than three months but less than one year to be short-term investments. All investments in marketable securities are classified as available for sale. Available-for-sale securities are reported at fair value, with temporary unrealized gains and losses excluded from earnings and reported as a separate component of stockholders’ equity, while other-than-temporary gains or losses are included in earnings. The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. Concentration of credit risk and significant customers: Cash, cash equivalents and investments are the primary exposure for the Company to concentrations of credit risk. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company deposits its cash in financial institutions that it believes are financially sound and have not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash. Further, management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, are subject to minimal credit risk. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. On March 10, 2023, Silicon Valley Bank (“SVB”) was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as receiver. On March 13, 2023, pursuant to a joint statement released by the U.S. Department of Treasury, the U.S. Federal Reserve, and the FDIC, the U.S. government provided assurance that all depositors would be fully protected. Thereafter, the FDIC transferred all deposits of SVB to a newly created bridge bank, named Silicon Valley Bridge Bank, N.A. (“SVBB”), which announced that it would fully honor existing credit facilities. On March 27, 2023, First Citizens BancShares, Inc. entered into an agreement with the FDIC to purchase all assets and liabilities of SVBB and confirmed it would honor existing credit facilities. The Amended and Restated Loan and Security Agreement with SVB required an exclusive relationship for our operating cash account, however in light of the events and status of SVB, we entered into an agreement in April 2023 which allows the Company to establish operating accounts and move an additional portion of our cash resources to another financial institution. There was no significant concentration in any single customer for the years ended December 31, 2023 and 2022. Fair value of financial instruments: The Company’s financial instruments consist of cash equivalents, short-term investments, accounts payable, accrued expenses, a corporate bond and note payable. The carrying amount of accounts payable and accrued expenses are considered a reasonable estimate of their fair value, due to the short-term maturity of these instruments. The Company’s cash equivalents and short-term investments are carried at fair value, determined according to the fair value hierarchy described below (see Note 13). The Company follows the guidance in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures, or ASC 820, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: Level 1: Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2: Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3: Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level I to Level 2 or Level 2 to Level 3. Property and equipment: Property and equipment is stated at cost less accumulated depreciation and any accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the asset. When parts of an item of property and equipment have different useful lives, they are accounted for as separate items (major components) of property and equipment. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: Furniture and fixtures 5 - 7 years Computer equipment and software 3 years Office equipment 3 years Leasehold improvements 3 - 7 years ( Or remaining term of the lease, if shorter ) Internal-use software 2 - 5 years Depreciation methods, useful lives and residual values are reviewed at least annually and adjusted, if appropriate. Impairment of long-lived assets: The Company periodically reviews the carrying amount of long-lived assets which consist of property and equipment, to determine whether current events or circumstances indicate that such carrying amounts may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset or an asset group to estimated undiscounted future net cash flows expected to be generated by the asset or asset group. If the carrying amount of an asset exceeds these estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the assets exceeds the fair value of the asset or asset group, based on discounted cash flows. Management judgment is necessary to estimate the fair value of asset groups. Accordingly, actual results could vary significantly from such estimates. During the year ended December 31, 2023, the Company recognized an impairment loss of $ 384 related to the sublease of a portion of its office space in Larkspur, California (see Note 7). The fair value measurement of future cash flows from the sublease agreement were estimated using an income approach to determine the present value. Leasehold improvements related to the subleased area are included in the impairment as the Company no longer receives economic benefits after it discontinues use of the space. The impairment loss was comprised of a write-down of $ 325 for the right-of-use asset and $ 59 for the leasehold improvements. The impairment loss is included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. The Company did not identify any circumstances that would warrant an impairment charge for any long-lived assets on the consolidated balance sheet at December 31, 2023. Internal-use software development costs: With respect to the Company’s software products sold under subscription arrangements with customers, costs incurred in the preliminary design and development stages of a project are expensed as incurred in accordance with FASB ASC 350-40, Internal-Use Software. Once a project has reached the application development stage and it is probable that the software will be completed for its intended function, certain internal, external, direct and indirect costs may be subject to capitalization. Generally, costs are capitalized until the technology is available for its intended use. Subsequent costs incurred for the development of future upgrades and enhancements, which are expected to result in additional functionality, follow the same protocol for capitalization. Capitalized software development costs are recorded in property and equipment on the Company’s consolidated balance sheets. Leases: The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the consolidated balance sheets as right-of-use assets and lease liabilities and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates or abatements we expect to receive from the lessor. Options to extend a lease are included in the expected lease term if exercise of the option is deemed reasonably certain. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilized the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. To estimate our incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since it does not currently have a rating agency-based credit rating. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. The Company has elected the practical expedient not to separate lease and non-lease components for real estate leases. Sublease: The Company recognizes sublease income on a straight-line basis over the sublease period. The Company recognizes sublease income as an offset to rent expense within operating expenses in the consolidated statements of operations and comprehensive loss as subleasing is not a primary business activity of the Company and is meant to offset occupancy costs. Deferred revenue: Deferred revenue represents payment received in advance of revenue being earned and is comprised of fees received in advance of the delivery or completion of the services and amounts received in instances when revenue recognition criteria have not been met. Deferred revenue associated with upfront payments for a subscription to the Company’s FDA-authorized video game product is amortized ratably over the subscription period. Earn-Out Liabilities: In connection with the Business Combination, holders of Legacy Akili common stock, Legacy Convertible Preferred Stock and warrants to purchase shares of Legacy Akili common stock (“Earn-Out Shareholders”) and employees or individual service providers holding options to purchase shares of Legacy Akili common stock, in each case as designated by the Board of Akili as an earn-out service provider prior to the Closing Date (“Earn-Out Service Providers”) received the contingent right to receive additional Common Stock upon the achievement of certain earn-out targets (the “Rights”). The Company concluded the issuance of Rights to Earn-Out Shareholders constitutes a deemed dividend and evaluated the Rights for classification under guidance applicable to financial instruments. In assessing classification, the Company considered ASC Subtopic 815-40 “Contracts in Entity’s Own Equity” and determined the Rights contain settlement provisions that preclude them from being indexed to the Company’s stock and accordingly liability classification is required. The Company concluded issuance of the Rights to Earn-Out Service Providers represents compensation in scope of ASC Topic 718, “Compensation - Stock Compensation.” In considering relevant classification guidance, the Company determined the Rights issued to Earn-Out Service Providers are liabilities because they are indexed to whether such Earn-Out Service Providers hold qualifying equity instruments when the earn-out targets are achieved. The fair value of the contingent earn-out consideration is estimated as of the Closing Date at the present value of the expected contingent earn-out consideration using a Monte Carlo Simulation Method (“MCSM”). The Company reviews the probability of achievement of the earn-out targets to determine the impact on the fair value of the earn-out consideration on a quarterly basis over the earn-out period. For Earn-Out Shareholders, the corresponding fair value was initially recorded against additional paid-in capital. Changes in the estimated fair value of the contingent earn-out consideration related to Earn-Out Shareholders are recorded in other income (expense) in the Consolidated Statements of Operations and Comprehensive Loss and are reflected in the period in which they are identified. For Earn-Out Service Providers, the corresponding fair value was initially recorded within operating expenses in the same functional category as the grantees' operating expenses. Changes in the estimated fair value of contingent earn-out consideration related to Earn-Out Service Providers is recorded as stock compensation for the period. Changes in the estimated fair value of the contingent earn-out consideration may materially impact or cause volatility in the Company's operating results. Transaction Costs: As part of the Business Combination, the Company allocated certain transaction costs to the Earn-out Shares based on the relative fair value of these instruments as compared to the other newly issued instruments. The portion of transaction costs allocated to these instruments was reflected as a reduction to cash and an increase in selling, general and administrative expense. The costs were determined to relate to future share issuances and not to the initial recapitalization and therefore they were expensed on the Closing Date. All costs allocated to the other newly issued instruments, which consisted of Common Stock, were recorded in total permanent equity as a reduction of additional paid-in capital. Revenue: The Company accounts for revenue recognition in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company generates revenue from contracts with caregivers and patients who purchase subscriptions to access EndeavorRx (“Clients”), the Company’s FDA-authorized video game treatment. Clients are billed in advance for the entire subscription term (new subscriptions are currently for 30 days). Along with the subscription to the video game product, Clients also receive reporting metrics and technical support services. The reporting metrics rely on gameplay data being sent back from EndeavorRx, which the Company analyzes in order to provide information on daily efforts and level completion to Clients throughout the subscription term via the EndeavorRx Insight app. The subscription to the video game product, reporting metrics and technical support services are combined as a single stand-ready performance obligation because while the components are separate performance obligations, they have the same method and pattern of recognition. Accordingly, the consideration is recognized ratably on an over time basis over the subscription period which begins once the access code is inputted into the game by the Client and game play has started. In June 2023, the Company released its EndeavorOTC over-the-counter product under the FDA’s COVID-19 Guidance. The Company generates revenue from customers who purchase subscriptions of variable term lengths (currently available as either one month or one year ) to access the video game treatment. Customers are billed in advance for the entire applicable subscription term. Along with the subscription to the video game treatment, the customers also receive technical support services and access to software updates. The technical support services and access to software updates were determined to be immaterial in the context of the contract primarily due to the fact that the underlying selective stimulus management engine (“SSME”) technology is not being updated throughout the subscription term, and therefore the primary functionality of the product is not changed during the term of the arrangement. As EndeavorOTC has significant stand-alone functionality that can be used immediately upon delivery, the performance obligation is considered complete upon delivery and all of the consideration is recognized at that point in time. The Company has generated revenue from a collaboration agreement with Shionogi. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations that consist of licenses and other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company has determined that the licenses and other promises under the Collaboration Agreement are a single combined performance obligation satisfied over time. The Company must select a single measure of progress that best depicts the Company’s measurement of progress. ASC 606-10-26-33 states that appropriate methods of measuring progress include output methods and input methods and notes that an entity should consider the nature of the good or service that the entity promised to transfer to the customer in determining the appropriate method for measuring progress. Since activities performed to research and validate one phase may be useful in researching and validating subsequent phases, the Company believes that an input method, which tracks the Company’s efforts required to perform the contracted activities during the contract term, is more representationally faithful than an output method, which might track the agreed upon deliverables that are not similar to one another. If an arrangement includes development and regulatory milestone payments or royalties, the Company evaluates whether the milestones or royalties are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone or royalty value is included in the transaction price. Payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The following table presents the Company’s revenue by product type: Year Ended 2023 2022 EndeavorOTC revenue $ 1,155 $ — EndeavorRx revenue 523 323 Total $ 1,678 $ 323 There was no collaboration revenue in either period. As of December 31, 2023, the Company has a contract liability related to EndeavorRx product revenue, which consists of amounts that have been paid but have not been recognized as revenue. All amounts are expected to be recognized as revenue within 12 months of the balance sheet date and are classified as current deferred revenue. The Company recognized $ 106 of product revenue in the year ended December 31, 2023 that was previously included in the December 31, 2022 deferred revenue balance. Contract Liabilities Product Balance at December 31, 2022 $ 106 Revenue recognized 523 Revenue deferred ( 529 ) Balance at December 31, 2023 $ 100 Cost of revenue: Cost of revenue includes personnel and related costs, third party contractor expenses, customer support costs, royalties, amortization of capitalized software related to our two commercialized products and software subscriptions related to our products and hosting fees. Sales of EndeavorRx incurred third-party pharmacy dispense fees and sales of EndeavorOTC incur Apple App Store and Google Play fees, both of which are included in cost of revenue. As the Company controls the product until it is transferred to the customer, it is considered the principal in the arrangement and all revenue and cost of revenue is shown gross in the Consolidated Statements of Operations and Comprehensive Loss. Research and development costs: Research and development costs are expensed as incurred. Research and development costs include personnel and related costs, consulting costs, external contract research and development expenses, as well as depreciation and utilities. The Company has several agreements with non-related entities to conduct research on behalf of the Company. The expenses incurred associated with these agreements are expensed as incurred within research and development costs. Advertising: The Company expenses advertising costs as incurred. Advertising expenses were $ 6,580 and $ 7,861 during the years ended December 31, 2023 and 2022 . Accounting for stock-based compensation: Stock-based compensation made to employees and non-employees, including stock options, restricted stock units (“RSUs”) and performance stock units with market conditions (“PSUs”), is measured based on the grant date fair value of the awards and is recognized as compensation expense typically on a straight-line basis over the period during which the share-based award holder is required to perform services in exchange for the award (the vesting period) for stock options and RSUs and on an accelerated attribution basis for each vesting tranche over the respective derived service period for PSUs. The Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified. The Company recognizes adjustments to stock compensation expense for forfeitures as they occur. The fair value of each stock option grant is estimated on the date of grant using the Black- Scholes option-pricing model. RSUs are measured based on the fair values of the underlying stock on the date of grant. We use the MCSM to estimate the fair value of PSUs. See Note 12 for further discussion of stock-based compensation. Income taxes: Deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and income tax basis of assets and liabilities using rates anticipated to be in effect when such temporary differences reverse. A change in tax rates is recognized in income in the period of the enactment date. A valuation allowance against net deferred tax assets is required if, based upon the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company also assesses the probability that the positions taken or expected to be taken in its income tax returns will be sustained by taxing authorities. A “more likely than not” (more than 50%) recognition threshold must be met before a tax benefit can be recognized. Tax positions that are more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position, are reflected in the Company’s consolidated financial statements. Tax positions are measured as the largest amount of tax benefit that is greater than 50 % likely of being realized upon settlement with a taxing authority that has full knowledge of all relevant information. The difference between the benefit recognized for a position and the tax benefit claimed on a tax return is referred to as an unrecognized tax benefit. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense. Comprehensive Loss: Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. Net Loss Per Share: The Company follows the two-class method when computing net loss per share, or EPS, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. Segment and Geographic Information: Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer, or CEO. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States. Emerging Growth Company Status: The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company, or EGC, such as Akili to take advantage of an extended transition period to comply with the new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected to use this extended transition period under the JOBS Act until such time the Company is no longer considered to be an EGC, which means that when a standard is issued or revised, it has different applications for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elect to “opt-out” of such extended transition period or (ii) no longer qualify as an EGC. Recently adopted accounting pronouncements: In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), as amended by ASU 2019-10. ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. ASU 2016-13 is effective for the Company for the annual reporting period beginning January 1, 2023 . The Company adopted this guidance for the year ended December 31, 2023, however there was no impact to the financial statements.

Business Combination

Business Combination	12 Months Ended
	Dec. 31, 2023
Business Combinations [Abstract]
Business Combination	3. Business Combination As discussed in Note 1, on August 19, 2022, the Company consummated the Business Combination pursuant to the Merger Agreement. The Business Combination was accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, SCS, who was the legal acquirer, was treated as the “acquired” company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Akili issuing stock for the net assets of SCS, accompanied by a recapitalization. Upon the Closing, holders of Legacy Akili common stock received shares of Common Stock in an amount determined by application of the exchange ratio of approximately 1.15 (the “Exchange Ratio”), which was based on Legacy Akili’s implied price per share prior to the Business Combination. For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted by applying the Exchange Ratio. The consolidated assets, liabilities and results of operations prior to the Business Combination are those of Legacy Akili. In connection with the Business Combination, approximately $ 31,438 of transaction related expenses and other costs were incurred. The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of changes in equity: Year ended December 31, 2022 Cash - SCS trust and cash (net of redemptions) $ 2,283 Cash - PIPE investors 162,000 Gross proceeds 164,283 Transaction related expenses and other costs paid at Closing (of which $ 8,850 represent the Company's transaction costs) ( 30,989 ) Transaction related expenses and other costs paid after Closing ( 449 ) Net proceeds from the Business Combination 132,845 In addition to the $ 8,850 paid at Closing noted in the table above, the Company incurred $ 4,077 in additional transaction costs related to certain legal, accounting, consulting and other third-party fees incurred. These transaction costs were incurred and paid during the year ended December 31, 2022. Of the Company's total transaction costs of $ 12,927 , $ 3,046 was allocated to the Earn-Out Shares and expensed upon the Closing, based on the relative fair value of the Earn-Out Shares as compared to the other newly issued instruments as part of the Business Combination. The remaining Company transaction costs were recorded in additional paid-in capital. The number of shares of Common Stock outstanding immediately following the Closing was as follows: Common Stock SCS public stockholders 227,522 SCS sponsor and independent director 6,890,000 Legacy Akili stockholders (1) 54,541,224 PIPE investors 16,200,000 Total shares of Common Stock immediately after Closing 77,858,746 (1) The number of Legacy Akili shares was determined from the shares of Legacy Akili shares outstanding immediately prior to the Closing converted at the Exchange Ratio of approximately 1.15 . The amount includes the cashless exercise of certain outstanding Akili Interactive Labs, Inc. warrants, which resulted in the issuance of 8,834 shares of Common Stock. All fractional shares were rounded down. Amount excludes the issuance of 7,536,461 Earn-Out Shares (as defined below), as the performance conditions have not yet been satisfied. Earn-Out Shares: Earn-Out Shareholders and Earn-Out Service Providers received the contingent right to receive additional shares of Common Stock upon the achievement of certain earn-out targets. Earn-Out Shareholders and Earn-Out Service Providers are eligible to receive up to 7,536,461 shares in the aggregate (the "Earn-Out Shares”) of additional Common Stock in three equal tranches upon the Company achieving $ 15.00 , $ 20.00 , or $ 30.00 , respectively, as its volume-weighted average price per share of Common Stock for any 20 trading days within a 30 consecutive trading day period (as adjusted for share splits, reverse share splits, share dividends, reorganizations, recapitalizations, reclassifications, combination, exchange of shares, or the like). As the Earn-Out Shares to Earn-Out Shareholders contain a settlement provision that precludes them from being indexed to the Company’s stock under ASC 815, Derivatives and Hedging , they are classified as liabilities. The Company accounts for the potential issuance of the Earn-Out Shares to Earn-Out Shareholders as a contingent consideration arrangement, a liability for which was initially valued and recorded using a MCSM for each earn-out period. Key inputs and assumptions were the Company’s stock price, expected term, volatility, the risk-free rate, and dividend yield. Some of these inputs are Level 3 assumptions that are updated each reporting period as the earn-out liabilities are recorded at fair value on a recurring basis. The Company revalued the earn-out liabilities as of December 31, 2023 and the change in the fair value of the earn-out liabilities was recorded in other income (expense) on the statement of operations. As the Earn-Out Shares to Earn-Out Service Providers are indexed to whether such Earn-Out Service Providers hold qualifying equity instruments when the earn-out targets are achieved, they are classified as a liability under ASC 718, " Compensation-Stock Compensation ". The Company accounts for the potential issuance of the Earn-Out Shares to Earn-Out Service Providers as the grant of a compensatory award under ASC 718. As there are no continuing service obligations, the awards were expensed on the date of the Business Combination and the fair value is updated each reporting period. The change in fair value is recorded as stock compensation for the period in the same functional category as the grantees' operating expenses. Earn-Out Shareholders Earn-Out Service Providers Total Fair value as of December 31, 2022 $ 4,778 $ 735 $ 5,513 Change in fair value ( 3,363 ) ( 518 ) ( 3,881 ) Fair value as of December 31, 2023 $ 1,415 $ 217 $ 1,632

Option and Collaboration Agreem

Option and Collaboration Agreements	12 Months Ended
	Dec. 31, 2023
Option And Collaboration Agreements [Abstract]
Option and Collaboration Agreements	4. Option and Collaboration Agreements Shionogi & Co., Ltd. On December 19, 2018, the Company entered into an Option and Collaboration Agreement (the “Collaboration Agreement”) with Shionogi & Co., Ltd (“Shionogi”), whereby the Company granted an option to Shionogi to develop and commercialize licensed digital therapeutic software products in specified territories. As part of the agreement, Shionogi made an upfront payment to the Company of $ 10,000 at the date of execution that provided Shionogi up to April 15, 2019 to continue to evaluate the technology. In March 2019, Shionogi exercised its option to license the technology in exchange for another $ 10,000 cash payment. In connection with Shionogi exercising its option to enter into the Collaboration Agreement, the Company issued a $ 5,000 corporate bond to Shionogi for cash, with an initial discount estimated to be $ 3,805 (see Note 9). With the execution of the option, the Company is eligible to receive development and commercial milestones of up to $ 105,000 . In addition, the Company will receive royalties on sales of the licensed products in Japan and Taiwan. In October 2019, the Company and Shionogi entered into a modification scope of work agreement. Shionogi paid the Company an additional fee of $ 387 as a result of the modification. As all obligations under the Collaboration Agreement were fulfilled, revenue of $ 24,192 was recognized by the end of 2021. The Company did no t recognize any milestones or royalties during the years ended December 31, 2023 and 2022. TALi Digital Limited On October 16, 2023, Akili Interactive Labs, Inc., a wholly owned subsidiary of the Company, and TALi Digital Limited mutually agreed to terminate the License, Development and Commercialization Agreement dated as of August 16, 2021 between such parties, effective as of October 16, 2023. As a result of the termination, no additional payments are due to TALi. During the year ended December 31, 2023, the Company did not make any payments for out of pocket costs related to this agreement. As of the termination date, the Company has not made any payments for milestones or royalties related to this agreement.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2023
Prepaid Expense, Current [Abstract]
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: December 31, 2023 2022 Prepaid insurance $ 1,008 $ 1,892 Prepaid clinical trials - 697 Other current assets 1,267 1,976 Prepaid expenses and other current assets $ 2,275 $ 4,565

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	6. Property and Equipment Property and equipment, net consisted of the following: December 31, 2023 2022 Furniture and fixtures $ 116 $ 184 Computer equipment and software 269 477 Office equipment 44 60 Leasehold improvements 885 975 Capitalized internal-use software costs 551 427 Total property and equipment 1,865 2,123 Less: accumulated depreciation and amortization ( 1,185 ) ( 1,204 ) Property and equipment, net $ 680 $ 919 Depreciation and amortization expense was $ 302 and $ 308 for the years ended December 31, 2023 and 2022 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Litigation: From time to time, the Company is a party to or can be threatened with litigation in the ordinary course of business. The Company regularly analyzes current information, including, as applicable, the Company`s defenses and insurance coverage, and, as necessary, provides accruals for probable and estimable liabilities for the eventual disposition of any matters. The Company was not a party to any material legal proceedings as of the years ended December 31, 2023 and 2022. Office Space: As of December 31, 2023 , the Company leases office space under a non-cancelable operating lease in Larkspur, California, which consists of approximately 43,600 square feet pursuant to a lease that will expire in November 2026 , in exchange for approximately $ 74 per month, subject to an annual 4 % increase each May. The Company provided a customary letter of credit in the amount of $ 250 as a security deposit, which is included in restricted cash within the consolidated balance sheets. In May 2023, the Company entered into a sublease agreement, pursuant to which the Company agreed to sublease approximately 5,716 rentable square feet of the Larkspur, California office space to a third party for a term commencing on June 1, 2023 and ending coterminous with the Larkspur, California lease in November 2026 , in exchange for the sum of approximately $ 23 per month, subject to an annual 4.0 % increase. The lease for office space in Boston, Massachusetts consisting of approximately 4,000 square feet expired in December 2023 . In November 2023, the Company entered into a membership agreement, pursuant to which the Company agreed to pay a monthly membership fee for the sum of approximately $ 9 per month for access to office space in Boston, Massachusetts, with such access commencing on January 1, 2024 . The agreement is for a one-year term and will automatically renew for successive one-year terms, subject to the Company’s right to terminate the agreement upon prior written notice and pursuant to the terms of the membership agreement and is classified as a short-term lease. These leases do not include any restrictions or covenants that had to be accounted for under the new lease guidance. During the years ended December 31, 2023 and 2022, the Company recognized $ 757 of rent expense, net of sublease payments received and $ 1,026 of rent expense, respectively. Net cash paid for the amounts included in the measurement of the operating lease liability on the consolidated balance sheet and operating activities in the consolidated statement of cash flow was $ 1,042 for the year ended December 31, 2023. The weighted average remaining lease term and incremental borrowing rate as of December 31, 2023 was 2.9 years and 7.6 % , respectively. Future lease payments for our noncancelable operating leases (excluding short-term leases) as of December 31, 2023 and a reconciliation to the carrying amount of the operating lease liability presented in the consolidated balance sheet as of December 31, 2023 is as follows: Years Ending December 31, Amounts 2024 $ 914 2025 950 2026 904 Total undiscounted payments due under operating leases 2,768 Less imputed interest ( 282 ) Total $ 2,486 Current operating lease liability $ 756 Non-current operating lease liability 1,730 Total $ 2,486

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: December 31, 2023 2022 Accrued bonus $ 2,355 $ 2,819 Accrued royalties 150 110 Accrued wages and benefits 200 1,281 Accrued clinical study expenses 12 292 Accrued consulting service expenses 129 401 Other accrued expenses 480 713 Total $ 3,326 $ 5,616

Corporate Bond

Corporate Bond	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Corporate Bond	. Corporate Bond In March 2019, in connection with Shionogi exercising its option to enter into the Collaboration Agreement, the Company issued a $ 5,000 corporate bond to Shionogi for cash. The corporate bond is unsecured and is subordinated to the obligations of the Company under indebtedness for borrowed money owed by the Company to any bank or other financial institution. The maturity date of the corporate bond is November 10, 2031 and does not bear interest during its term (fixed interest rate of 0.0 %). The corporate bond is prepayable by the Company at any time without penalty. The repayment of the corporate bond can be accelerated upon the termination of the Collaboration Agreement or upon the occurrence of an event of default (as defined), in both cases without penalty. The Company determined that the interest rate on the corporate bond did not reflect a market interest rate that the Company would expect to incur on a similar instrument issued apart from the Collaboration Agreement. As such, the Company estimated the market rate of interest for a similar instrument (as 12.0 %) and recorded a discount on the corporate bond at issuance in order to impute interest at this rate over the term of the instrument. The initial discount on the corporate bond was estimated to be $ 3,805 . As the corporate bond was issued in connection with the Collaboration Agreement, the Company also added the estimated initial discount as a component of the transaction price (and an adjustment to revenue recognized) related to the Collaboration Agreement. The Company amortizes the initial discount to interest expense using the effective interest method over the term of the corporate bond. The Company recognized amortization expense of $ 220 and $ 196 related to the discount on the Corporate Bond as a component of interest expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022, respectively. The carrying amount of the corporate bond is as follows: 2023 2022 Corporate Bond $ 5,000 $ 5,000 Unamortized discount on Corporate Bond ( 2,946 ) ( 3,166 ) Corporate Bond, net of discount $ 2,054 $ 1,834

Note Payable

Note Payable	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Note Payable	10. Note Payable Amended and Restated Loan and Security Agreement On May 25, 2021, the Company entered into an Amended and Restated Loan and Security Agreement with Silicon Valley Bank (“SVB”) and SVB Innovation Credit Fund VIII, L.P. (“SVB Innovation Fund”) (collectively, the “Lenders”). In December 2022, we entered into a Joinder and First Loan Modification Agreement with SVB (the "Amended SVB Term Loan"). As described in Note 2, First Citizens BancShares, Inc. entered into an agreement to purchase all assets and liabilities of SVBB and will fully honor the existing Amended SVB Term Loan. The Company borrowed $ 5,000 in May 2021 and $ 10,000 in June 2022 and made interest-only payments through May 2023 before beginning to repay the outstanding principal in 24 equal monthly payments on the first day of each month beginning June 1, 2023, plus interest. The maturity date of the Amended and Restated Loan and Security Agreement is May 1, 2025 . The Amended and Restated Loan and Security Agreement accrues interest on each advance at a per annum rate of the greater of (a) the Wall Street Journal prime rate plus 3.75 % or (b) 7.0 %. The Company can elect to prepay all, but not less than all, of the advances drawn prior to the maturity date. The Company will be required to pay a prepayment fee, calculated by multiplying the outstanding principal balance outstanding immediately prior to such prepayment by 1.0 %. The Company will be required to make a final payment equal to 5.0 % of the total amounts drawn from each tranche (the “Final Payment”), due upon the earliest of maturity, prepayment or termination of the amounts drawn under the Amended and Restated Loan and Security Agreement. The Loan and Security Agreement is secured by substantially all of the Company’s personal property assets, including accounts receivable, equipment, license agreements, general intangibles, inventory and investment property, and all of the proceeds and products of the foregoing. The Company is also subject to certain financial and non-financial covenants in the Loan and Security Agreement, including requirements to maintain operating and deposit accounts with the lender and restrictions on certain corporate actions. Upon closing of the Amended and Restated Loan and Security Agreement, the Company entered into warrant agreements with the Lenders (“Warrant Agreements”). As part of the Warrant Agreements, the Company issued fully-vested warrants to purchase 84,350 shares of common stock to the Lenders with an exercise price of $ 3.82 per share with a fair value of $ 268 on the date of issuance (see Note 11 for details). As a result of the $ 10,000 draw in June 2022, warrants to purchase 31,242 shares became available with a fair value of $ 282 . In relation to the entering into the Amended and Restated Loan and Security Agreement, the Company incurred a total of $ 559 of debt issuance costs (including the fair value of the warrants granted to the Lenders, plus the $ 250 Final Payment). The Company incurred an additional $ 782 of debt issuance costs related to the $ 10,000 draw in June 2022 (including the fair value of the warrants granted to the Lenders, plus the $ 500 Final Payment). The Company is amortizing the deferred issuance costs to interest expense on the effective interest method through the maturity date of the Amended and Restated Loan and Security Agreement. At December 31, 2023, the Company had outstanding principal of $ 10,625 and there is no remaining available undrawn debt. The Company recognized non-cash interest expense related to debt issuance costs of $ 503 and $ 341 for the years ended December 31, 2023 and 2022, respectively. The Company recognized selling, general and administrative expense related to loan commitment fees of $ 42 and $ 211 for the years ended December 31, 2023 and 2022 respectively. The interest rate in effect was 12.3 % and 11.3 % as of December 31, 2023 and 2022, respectively. The weighted average interest rate was 11.9 % and 9.2 % for the years ended December 31, 2023 and 2022 , respectively. At December 31, 2023, the carrying amount of the note payable (excluding the current portion of $ 7,500 ) is as follows: Outstanding principal $ 10,625 Note payable, short term ( 7,500 ) Final payment 750 Unamortized debt issuance costs ( 430 ) Note payable, long term (net of debt issuance costs) $ 3,445 Future minimum principal payments due under the Amended and Restated Loan and Security Agreement, excluding the Final Payment, are as follows: Years Ending December 31, 2024 $ 7,500 2025 3,125 Total $ 10,625

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Capital Stock	11. Capital Stock The Company's authorized capital stock consists of 1,000,000,000 shares of Common Stock, par value $ 0.0001 per share and 100,000,000 shares of preferred stock, par value $ 0.0001 per share . As of December 31, 2023, there were 78,356,527 shares of Common Stock issued and outstanding and 133,578 warrants outstanding to purchase Common Stock. There were no shares of preferred stock issued and outstanding. The holders of the Common Stock are entitled to one vote for each share of Common Stock. The holders of Common Stock shall be entitled to receive dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of Common Stock shall be entitled to share ratably in the remaining assets of the Company available for distribution. The Board or any authorized committee thereof is authorized to issue shares of preferred stock and to fix the designations, powers, including voting powers, full or limited, or no voting powers, preferences and the relative, participating, optional or other special rights of the shares of each series and any qualifications, limitations and restrictions thereof. Legacy Convertible Preferred Stock: Prior to the Business Combination, Legacy Akili had issued Series A-1 convertible preferred stock, Series A-2 convertible preferred stock, Series B convertible preferred stock, Series C convertible preferred stock and Series D convertible preferred stock, collectively referred to as the “Legacy Convertible Preferred Stock.” In connection with the Business Combination, the Legacy Convertible Preferred Stock was retroactively adjusted, converted into Common Stock at an exchange ratio of approximately 1.15 , and reclassified to permanent equity as a result of the reverse recapitalization. As of December 31, 2023, there is no Legacy Convertible Preferred Stock authorized, issued or outstanding. Common Stock Warrants: In May 2021, the Company entered into the Amended and Restated Loan and Security Agreement (see note 10). In conjunction with this modification, the Company issued warrants to the Lenders to purchase a total of 224,938 shares of common stock with an exercise price of $ 3.82 per share, of which, 84,350 were fully vested and immediately exercisable. These warrants were determined to be a separate freestanding instrument from the Amended and Restated Loan and Security Agreement. The Company also concluded that the remaining warrants that could vest in future periods in connection with additional loan advances will be treated as separate issuances if and when they are issued. In connection with the June 2022 draw, warrants to purchase an additional 31,242 shares of common stock became vested. The Company considered the accounting for the warrants and concluded that they met the requirements for equity classification under ASC 815-40. Upon initial issuance, the vested warrants to purchase the Company’s common stock were recorded at fair value. The Company utilized the Black- Scholes option valuation approach to value the common warrants that were issued, resulting in an estimated fair value of $ 268 in May 2021 and $ 282 in June 2022. The Company recorded this amount as an increase to additional paid-in capital and an increase to debt issuance costs (see Note 10). The Company determined the fair value of the warrants using the Black-Scholes option model with the following assumptions: Amended and Restated Loan and Security Agreement Warrants May 2021 June 2022 Fair value of common stock $ 3.82 $ 10.06 Expected volatility 95.00 % 96.56 % Expected term (in years) 10.00 8.91 Risk-free interest rate 1.56 % 3.23 % Expected dividend yield 0.00 % 0.00 % In August 2020, the Company entered into the First Loan Modification Agreement with SVB. In conjunction with this modification, the Company issued warrants to the lender, of which, 17,986 are fully vested and outstanding as of December 31, 2023. The warrants have an exercise price of $ 5.95 per share. Employee Stock Purchase Plan In connection with the Closing, the Company adopted the 2022 Employee Stock Purchase Plan (the “2022 ESPP”). The 2022 ESPP is a shareholder-approved plan under which substantially all employees may voluntarily enroll to purchase the Company’s Common Stock through payroll deductions at a price equal to 85 % of the lower of the fair market values of the stock as of the offering date or the exercise date, provided that no offering shall exceed 27 months. An employee’s payroll deductions under the 2022 ESPP are limited to 15 % of the employee’s compensation and employees may not purchase more than $ 25,000 of stock during any calendar year. A total of 1,167,881 shares of our Common Stock are reserved and authorized for issuance under the 2022 ESPP. In addition, the number of shares of Common Stock available for issuance under the 2022 ESPP is automatically increased each January 1 of each calendar year beginning on January 1, 2023, and ending in 2031, by the least of (i) the excess (if any) of (A) 1 % of the outstanding shares issued and outstanding on the immediately preceding December 31st (excluding any shares reserved for issuance under equity-based plans of Akili, Inc. including the 2022 Stock Option and Incentive Plan and the 2022 ESPP) over (B) the number of shares of stock then reserved for issuance under the 2022 ESPP as of such date, (ii) 1,167,881 or (iii) such number of shares determined by the administrator. Through December 31, 2023 , no shares have been issued under the 2022 ESPP.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Stock-Based Compensation	12. Stock-Based Compensation 2011 Stock Incentive Plan: Prior to the Business Combination, the Company’s 2011 Stock Incentive Plan (the “2011 Plan”) allowed the Company to grant incentive stock options, nonqualified stock options, and restricted stock to employees, directors, and nonemployees of the Company. Upon the Closing, the remaining unallocated share reserve under the 2011 Plan was cancelled and no new awards will be granted under such plan. Awards outstanding under the 2011 Plan were assumed by Akili, Inc. upon the Closing and continue to be governed by the terms of the 2011 Plan. 2022 Stock Option and Incentive Plan: In 2022, the Board approved the 2022 Stock Option and Incentive Plan, (the “2022 Plan”), which provides for the grant of incentive stock options, nonqualified stock options, and restricted stock to employees, directors, and nonemployees of the Company up to an aggregate of 12,813,781 shares of the Company’s Common Stock. During the year ended December 31, 2023, the Company incurred cash outflows of $ 118 related to the payment of withholding taxes for vested RSUs. These cash outflows are presented within net cash provided by financing activities in the consolidated statements of cash flows. Share-based compensation expense related to stock options, RSUs, PSUs, and the expense related to Earn-Out Service Providers, is classified in the consolidated statements of operations and comprehensive loss as follows: Year Ended 2023 2022 Research and development $ 2,526 $ 3,493 Selling, general and administrative 4,281 5,816 Total $ 6,807 $ 9,309 Included in the years ended December 31, 2023 and 2022 balances in the table above is $( 518 ) and $ 735 , respectively, of stock-based compensation related to the potential issuance of the Earn-Out Shares to Earn-Out Service Providers, as described in Note 3. Stock Options: The terms of the stock option grants, including the exercise price per share and vesting periods, are determined by the Board or by the compensation committee of the Board, as applicable. Stock options are typically granted at exercise prices equal to the fair value of our common stock at the date of grant. Our stock options typically vest at a rate of 25 % after one year from the vesting commencement date and then every six months over an additional three-year period. While the vesting schedule noted is typical, stock options have been issued under other vesting schedules. These alternative schedules include, but are not limited to (i) vesting at a rate of 25 % every six months for two years , (ii) vesting at a rate of 16.67 % every six months for three years , and (iii) vesting at a rate of 12.5 % every six months for four years . The stock options expire ten years from the grant date or within 90 days of employee termination. The following is a summary of stock option activity for the year ended December 31, 2023 : Number of Weighted- Weighted- Aggregate Balance at December 31, 2022 12,190,970 $ 3.98 7.36 Granted 5,199,280 $ 0.86 Cancelled ( 2,769,719 ) $ 3.58 Exercised ( 28,778 ) $ 0.03 Balance at December 31, 2023 14,591,753 $ 2.94 7.31 $ 285 Exercisable December 31, 2023 7,593,913 $ 3.71 5.53 $ 99 Options vested and expected to vest, December 31, 2023 14,591,753 $ 2.94 7.31 $ 285 During the year ended December 31, 2023 the Company extended the exercise period for vested options from three months to two years for 69 terminated employees. Incremental compensation expenses related to this modification recorded during the year ended December 31, 2023 was $ 208 . The fair value of all option activity was estimated at the date of grant using a Black-Scholes model with the following weighted-average assumptions for the years ended December 31, 2023 and 2022: Year Ended 2023 2022 Fair value of Common Stock $ 0.86 $ 5.03 Expected volatility 104.32 % 99.19 % Expected term (in years) 5.92 5.93 Risk-free interest rate 4.10 % 3.34 % Expected dividend yield 0.00 % 0.00 % Fair value of Common Stock: The fair value of the underlying common stock was determined by the Board until the Company became listed on an established stock exchange. The fair value was based upon a variety of factors, including the results obtained from independent third-party valuations, the Company’s financial position and historical financial performance, the status of technological developments within the Company’s products, the composition and ability of the current clinical and management team, an evaluation or benchmark of the Company’s competition, the current business climate in the marketplace, the illiquid nature of the common stock, arm’s length sales of the Company’s capital stock (including preferred stock), the effect of the rights and preferences of the preferred stockholders, and the prospects of a liquidity event, among others. Expected volatility: As there is not sufficient historical volatility for the expected term of the options, the Company used an average historical share price volatility based on an analysis of reported data for a peer group of comparable companies, which were selected based upon industry similarities. Expected term (in years): Expected term represents the period that the Company’s share option grants are expected to be outstanding. There is not sufficient historical share exercise data to calculate the expected term of the options. Therefore, the Company utilizes the “simplified” method for all options granted to value share option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. Risk-free interest rate: The Company determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant. Expected dividend yield: The Company does not anticipate paying any dividends in the foreseeable future. The weighted average grant-date fair value of stock options granted to employees during the years ended December 31, 2023 and 2022 was $ 0.70 and $ 3.94 per share, respectively. During the years ended December 31, 2023 and 2022, the aggregate intrinsic value of stock option awards exercised was $ 40 and $ 504 , respectively. Aggregate intrinsic value represents the difference between the exercise price and the fair value of the underlying Common Stock on the date of exercise. As of December 31, 2023 there was $ 10,219 of unrecognized compensation cost related to unvested stock option grants to employees, which is expected to be recognized over a weighted-average period of 2.2 years. Restricted Stock Units: The Company began issuing RSUs to its employees in 2022. RSUs are equity awards granted to employees that entitle the holder to shares of the Company’s common stock when the awards vest. RSUs granted to newly hired employees typically vest 25 % on the first vesting date, which occurs approximately one year after the date of grant, and ratably each six months of the ensuing three year period. RSUs have been issued under other vesting schedules. These alternative schedules include, but are not limited to, (i) vesting at a rate of 16.67 % every six months over three years , (ii) vesting at a rate of 12.5 % every six months over four years , and (iii) vesting at a rate of 25 % every six months over two years . RSUs are measured based on the fair value of the Company’s common stock on the date of grant. The following table summarizes RSU activity for the year ended December 31, 2023: Number of Weighted- Balance at December 31, 2022 801,401 $ 2.30 Granted 3,121,125 $ 0.82 Vested ( 321,739 ) $ 2.08 Forfeited ( 601,950 ) $ 1.74 Balance at December 31, 2023 2,998,837 $ 0.89 As of December 31, 2023 there was $ 2,435 of unrecognized compensation cost related to unvested RSUs under the 2022 Plan, which is expected to be recognized over a weighted-average period of 2.5 years. Performance Stock Units: PSUs are equity awards granted to employees that, upon vesting, entitle the holder to shares of the Company’s common stock. Under the 2022 Plan, the Company granted PSUs that will vest, if at all, on a graded basis during the five-year period commencing on November 2, 2022, subject to the achievement of specified performance goals related to the volume-weighted average closing price of the Company’s common stock over a 30 -trading day period. As such, these awards are considered to contain a market condition. All PSUs are subject to continued employment on the date of vesting. The following table summarizes PSU activity for the year ended December 31, 2023: Number of Weighted- Balance at December 31, 2022 4,554,408 $ 1.50 Granted — n/a Vested — n/a Forfeited ( 2,526,274 ) $ 1.50 Balance at December 31, 2023 2,028,134 $ 1.50 Compensation cost associated with PSUs is recognized on a straight-line basis over the derived service period of each of the three vesting tranches, which vest upon the achievement of three different volume-weighted average closing prices of the Company’s common stock. The Company determines the grant-date fair values of PSUs utilizing a MCSM. The Company’s use of a MCSM requires the use of the following inputs: Current stock price : the closing stock price as quoted on Nasdaq as of November 2, 2022 was $ 2.30 . Risk-free interest rate: the risk-free interest rate of 4.3 % was based on the U.S. Treasury rate at the time of grant commensurate with the remaining term of the PSUs. Expected term : the expected term is the five-year term of the PSUs. Expected volatility : the volatility rate as of November 2, 2022 was 95.0 %. The volatility rate was determined using an average of historical volatilities over the expected term of selected industry peers deemed comparable to the Company. Expected dividend yield : the expected dividend yield is zero as it is not expected that the Company will declare dividends on Common Stock during the expected term. As of December 31, 2023, there was $ 1,737 of unrecognized compensation cost related to unvested PSUs, which is expected to be recognized over a weighted average period of approximately 1.6 years.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities	13. Fair Value of Financial Assets and Liabilities The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values: Fair Value Measurements as of December 31, 2023 Description Level 1 Level 2 Level 3 Total Assets Cash equivalents: Money market funds $ 61,539 $ - $ - $ 61,539 Liabilities Long-term liabilities: Earn-out liabilities $ - $ - $ 1,632 $ 1,632 Fair Value Measurements as of December 31, 2022 Description Level 1 Level 2 Level 3 Total Assets Cash equivalents: Money market funds $ 32,829 $ - $ - $ 32,829 Short-term investments: United States treasuries 82,034 - - 82,034 Total assets $ 114,863 $ - $ - $ 114,863 Liabilities Long-term liabilities: Earn-out liabilities - - 5,513 5,513 Total liabilities $ - $ - $ 5,513 $ 5,513 The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2023 and 2022. As of December 31, 2023 and 2022, the Company’s cash equivalents consisted of money market funds with original maturities of less than 90 days from the date of purchase. As of December 31, 2023 , the Company did not hold short-term investments. As of December 31, 2022, the Company’s short-term investments consisted of United States treasuries with original maturities of more than three months but less than one year . Earn-out liabilities — Upon the Closing, the Earn-Out Shares were accounted for as a liability because the triggering events that determine the number of shares to be earned (the “Triggering Events”) included events that were indexed to the Common Stock of the Company, with the change in fair value recognized in “Change in estimated fair value of earn-out liabilities” in the consolidated statement of operations. The estimated fair value of the Earn-out Shares was determined using a MCSM using the following assumptions at December 31, 2023: Price target : price target as defined in the Merger Agreement for each Triggering Event: • Triggering Event I is $ 15.00 per share • Triggering Event II is $ 20.00 per share • Triggering Event III is $ 30.00 per share Current stock price : the closing stock price as quoted on Nasdaq as of December 31, 2023 was $ 0.49 . Expected term : the expected term is 3.6 years as of December 31, 2023, which is the remaining term of the earn-out period. Expected volatility : the volatility rate as of December 31, 2023 was 119.5 %. The volatility rate was determined using an average of historical volatilities over the expected term of selected industry peers deemed comparable to the Company. Expected dividend yield : the expected dividend yield is zero as it is not expected that the Company will declare dividends on Common Stock during the expected term. See Note 3 for a table that reconciles the change in fair value of the earn-out liabilities valued using Level 3 inputs.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes The provision for income taxes consists of the following components: Years Ended December 31, 2023 2022 Current Federal $ — $ — State 53 19 Total current expense (benefit) 53 19 Deferred Federal - - State - - Total deferred expense (benefit) $ — $ — Total tax recognized $ 53 $ 19 A reconciliation setting forth the differences between effective tax rate of the Company as well as the U.S. federal statutory tax rate is as follows: Years Ended December 31, 2023 2022 Benefit at federal statutory rate 21.00 % 21.00 % State taxes 4.73 % 54.48 % Credits 1.38 % 13.63 % Transaction costs 0.00 % ( 6.22 %) Gain on earn-out shares 1.19 % 218.69 % Share-based payment measurement ( 0.78 %) ( 10.45 %) Other ( 0.10 %) 2.56 % Change in valuation allowance ( 27.51 %) ( 293.93 %) Effective tax rate ( 0.09 %) ( 0.24 %) Significant components of the Company’s deferred tax assets and liabilities are as follows: Years Ended December 31, 2023 2022 Deferred tax assets: Operating tax losses $ 67,464 $ 55,350 Research credits 8,586 7,416 Temporary differences 1,240 1,337 Research and development costs 6,799 4,823 Start-up costs 2,075 2,197 Lease liability 617 847 Share based payments 4,484 3,298 Gross deferred tax assets 91,265 75,268 Valuation Allowance ( 90,364 ) ( 74,010 ) Deferred tax assets, Less: valuation allowance 901 1,258 Deferred tax liabilities: Right-of-use asset ( 391 ) ( 664 ) Other temporary differences ( 510 ) ( 594 ) Deferred tax liabilities ( 901 ) ( 1,258 ) Total $ — $ — Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amount used for income tax purposes. At December 31, 2023, the Company has federal net operating loss carryforwards totaling $ 275,482 of which $ 31,208 begin to expire in 2031 and $ 244,274 can be carried forward indefinitely. At December 31, 2023, the Company had state net operating loss carryforwards totaling $ 162,969 , which begin to expire in 2031 , as well as other temporary differences that will be available to offset regular taxable income during the carryforward period. Additionally, at December 31, 2023, the Company has federal R&D credit carryforwards totaling $ 6,330 which begin to expire in 2039 , state R&D credit carryforwards totaling $ 2,856 which begin to expire in 2033 . The net change in the valuation allowance for deferred tax assets was an increase of $ 16,354 and $ 27,723 for the years ended December 31, 2023 and 2022, respectively. This increase for the years ended December 31, 2023 and 2022 was primarily due to the generation of net operating loss carryforwards, capitalized R&D expenditures as required by changes to the tax laws from the TCJA as described below, and capitalized start-up costs. On December 22, 2017, the Tax Cuts and Jobs Act (“TCJA”) was signed into law. Under the TCJA provisions, effective with tax years beginning on or after January 1, 2022, taxpayers can no longer immediately expense qualified research and development (“R&D”) expenditures and are required to capitalize and amortize the costs under section 174. Accordingly, the Company capitalized $ 13,906 and $ 20,859 of R&D expenses as of December 31, 2023 and 2022, respectively. These costs will be amortized for tax purposes over 5 years for R&D performed in the U.S. and over 15 years for R&D performed outside the U.S. Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards and research and development credits. Under the applicable accounting standards, management has considered the Company’s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of domestic deferred tax assets. Accordingly, a full valuation allowance has been established at December 31, 2023 as the Company is in development stage and does not have assurance of future income as the Company expects to generate continued losses while in development. Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Section 382 and 383 of the Internal Revenue Code, and it may complete future financings that could result in a change in control in the future. The Company has not, as yet, conducted a study to determine if any such changes have occurred that could limit its ability to use the net operating loss and tax credit carryforward. Also, the Company has undertaken only a preliminary analysis of its research and experimentation credits. In order to substantiate fully such credits it intends to complete a full credit study before such credits are utilized on its tax return. The Company accounts for uncertain tax positions pursuant to ASC 740 which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with a taxing authority that has full knowledge of all relevant information. As of December 31, 2023 and 2022 , the Company has no t recorded any unrecognized tax benefits. The Company has not, as yet, conducted a study of research and development tax credit carryforwards. This study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development tax credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheets or consolidated statement of operations and comprehensive loss if an adjustment was required. The Company does not expect any material changes in the unrecognized tax benefits within the next twelve months.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	15. Net Loss Per Share The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: Year Ended 2023 2022 Numerator: Net loss $ ( 59,493 ) $ ( 7,964 ) Dividends on Series D convertible preferred stock - ( 7,383 ) Redemption value of Series D convertible preferred stock - ( 3,692 ) Net loss attributable to common stockholders - basic and diluted $ ( 59,493 ) $ ( 19,039 ) Denominator: Weighted average common stock outstanding 78,197,107 29,878,041 Net loss per share attributable to common stockholders - basic and diluted $ ( 0.76 ) $ ( 0.64 ) For periods in which the Company reports a net loss attributable to common stockholders, potentially dilutive securities have been excluded from the computation of diluted net loss per share as their effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: Year Ended 2023 2022 Warrants to purchase Common Stock 133,578 242,924 Stock options to purchase Common Stock 14,591,753 12,190,970 Earn-out shares 7,536,461 7,536,461 Unvested RSUs 2,998,837 801,401 Unvested PSUs 2,028,134 4,554,408 Total 27,288,763 25,326,164

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Employee Benefit Plan	16. Employee Benefit Plan The Company has a 401(k) retirement plan in which substantially all U.S. employees are eligible to participate. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The total contribution matching expense for the Company was $ 689 and $ 784 for the years ended December 31, 2023 and 2022 , respectively.

Restructuring Charges

Restructuring Charges	12 Months Ended
	Dec. 31, 2023
Restructuring Charges [Abstract]
Restructuring Charges	17. Restructuring Charges On January 12, 2023 , the Company announced a restructuring of its operations and a reduction in workforce. As a result of the restructuring, the Company incurred a restructuring charge of $ 2,329 associated primarily with severance and other termination-related benefits related to 48 full-time employees, representing approximately 31 % of the employee base at the time of the restructuring. All costs associated with the restructuring were recorded within operating expenses in the same functional category as the employees' operating expenses in the quarter ended March 31, 2023. The restructuring reduced costs related to certain of the Company’s pipeline programs in order to prioritize certain of its commercial efforts and its ADHD label expansion programs. On September 13, 2023 , the Company announced a further restructuring of its operations and a reduction in workforce. As a result of the restructuring, the Company incurred a restructuring charge of $ 2,401 associated primarily with severance and other termination-related benefits related to 47 full-time employees, representing approximately 40 % of the employee base at the time of the restructuring. All costs associated with the restructuring were recorded within operating expenses in the same functional category as the employees' operating expenses in the quarter ended September 30, 2023. The restructuring reduced costs related primarily to the Company’s field sales force and market access teams in order to implement its announced plan to transition from a prescription to a non-prescription business model. As of December 31, 2023, there are unpaid restructuring expenses of $ 94 in accrued expenses and other current liabilities.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company, after elimination of all intercompany accounts and transactions.
Use of estimates	Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of the earn-out liability and the valuation of stock-based awards. On an ongoing basis, management evaluates its estimates, including those related to accrued liabilities and stock-based compensation expense. Actual results could differ from the Company’s estimates.
Cash and cash equivalents	Cash and cash equivalents: The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market accounts, are stated at fair value.
Restricted cash	Restricted cash: Restricted cash consists of two savings accounts. One is required as collateral for the business credit cards which remains restricted until the contract is terminated and the obligation is paid in full. The second is a security deposit for an office lease in Larkspur, California and remains in place until the lease ends in 2026.
Investments	Investments: The Company considers all investments with original maturities of more than three months but less than one year to be short-term investments. All investments in marketable securities are classified as available for sale. Available-for-sale securities are reported at fair value, with temporary unrealized gains and losses excluded from earnings and reported as a separate component of stockholders’ equity, while other-than-temporary gains or losses are included in earnings. The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss.
Concentration of credit risk and significant customers	Concentration of credit risk and significant customers: Cash, cash equivalents and investments are the primary exposure for the Company to concentrations of credit risk. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company deposits its cash in financial institutions that it believes are financially sound and have not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash. Further, management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, are subject to minimal credit risk. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. On March 10, 2023, Silicon Valley Bank (“SVB”) was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as receiver. On March 13, 2023, pursuant to a joint statement released by the U.S. Department of Treasury, the U.S. Federal Reserve, and the FDIC, the U.S. government provided assurance that all depositors would be fully protected. Thereafter, the FDIC transferred all deposits of SVB to a newly created bridge bank, named Silicon Valley Bridge Bank, N.A. (“SVBB”), which announced that it would fully honor existing credit facilities. On March 27, 2023, First Citizens BancShares, Inc. entered into an agreement with the FDIC to purchase all assets and liabilities of SVBB and confirmed it would honor existing credit facilities. The Amended and Restated Loan and Security Agreement with SVB required an exclusive relationship for our operating cash account, however in light of the events and status of SVB, we entered into an agreement in April 2023 which allows the Company to establish operating accounts and move an additional portion of our cash resources to another financial institution. There was no significant concentration in any single customer for the years ended December 31, 2023 and 2022.
Fair value of financial instruments	Fair value of financial instruments: The Company’s financial instruments consist of cash equivalents, short-term investments, accounts payable, accrued expenses, a corporate bond and note payable. The carrying amount of accounts payable and accrued expenses are considered a reasonable estimate of their fair value, due to the short-term maturity of these instruments. The Company’s cash equivalents and short-term investments are carried at fair value, determined according to the fair value hierarchy described below (see Note 13). The Company follows the guidance in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures, or ASC 820, which defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: Level 1: Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2: Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3: Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level I to Level 2 or Level 2 to Level 3.
Property and equipment	Property and equipment: Property and equipment is stated at cost less accumulated depreciation and any accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the asset. When parts of an item of property and equipment have different useful lives, they are accounted for as separate items (major components) of property and equipment. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: Furniture and fixtures 5 - 7 years Computer equipment and software 3 years Office equipment 3 years Leasehold improvements 3 - 7 years ( Or remaining term of the lease, if shorter ) Internal-use software 2 - 5 years Depreciation methods, useful lives and residual values are reviewed at least annually and adjusted, if appropriate.
Impairment of long-lived assets	Impairment of long-lived assets: The Company periodically reviews the carrying amount of long-lived assets which consist of property and equipment, to determine whether current events or circumstances indicate that such carrying amounts may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset or an asset group to estimated undiscounted future net cash flows expected to be generated by the asset or asset group. If the carrying amount of an asset exceeds these estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the assets exceeds the fair value of the asset or asset group, based on discounted cash flows. Management judgment is necessary to estimate the fair value of asset groups. Accordingly, actual results could vary significantly from such estimates. During the year ended December 31, 2023, the Company recognized an impairment loss of $ 384 related to the sublease of a portion of its office space in Larkspur, California (see Note 7). The fair value measurement of future cash flows from the sublease agreement were estimated using an income approach to determine the present value. Leasehold improvements related to the subleased area are included in the impairment as the Company no longer receives economic benefits after it discontinues use of the space. The impairment loss was comprised of a write-down of $ 325 for the right-of-use asset and $ 59 for the leasehold improvements. The impairment loss is included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. The Company did not identify any circumstances that would warrant an impairment charge for any long-lived assets on the consolidated balance sheet at December 31, 2023.
Internal-use software development costs	Internal-use software development costs: With respect to the Company’s software products sold under subscription arrangements with customers, costs incurred in the preliminary design and development stages of a project are expensed as incurred in accordance with FASB ASC 350-40, Internal-Use Software. Once a project has reached the application development stage and it is probable that the software will be completed for its intended function, certain internal, external, direct and indirect costs may be subject to capitalization. Generally, costs are capitalized until the technology is available for its intended use. Subsequent costs incurred for the development of future upgrades and enhancements, which are expected to result in additional functionality, follow the same protocol for capitalization. Capitalized software development costs are recorded in property and equipment on the Company’s consolidated balance sheets.
Leases	Leases: The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the consolidated balance sheets as right-of-use assets and lease liabilities and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates or abatements we expect to receive from the lessor. Options to extend a lease are included in the expected lease term if exercise of the option is deemed reasonably certain. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilized the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. To estimate our incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since it does not currently have a rating agency-based credit rating. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. The Company has elected the practical expedient not to separate lease and non-lease components for real estate leases.
Sublease	Sublease: The Company recognizes sublease income on a straight-line basis over the sublease period. The Company recognizes sublease income as an offset to rent expense within operating expenses in the consolidated statements of operations and comprehensive loss as subleasing is not a primary business activity of the Company and is meant to offset occupancy costs.
Deferred revenue	Deferred revenue: Deferred revenue represents payment received in advance of revenue being earned and is comprised of fees received in advance of the delivery or completion of the services and amounts received in instances when revenue recognition criteria have not been met. Deferred revenue associated with upfront payments for a subscription to the Company’s FDA-authorized video game product is amortized ratably over the subscription period.
Earn-Out Liabilities	Earn-Out Liabilities: In connection with the Business Combination, holders of Legacy Akili common stock, Legacy Convertible Preferred Stock and warrants to purchase shares of Legacy Akili common stock (“Earn-Out Shareholders”) and employees or individual service providers holding options to purchase shares of Legacy Akili common stock, in each case as designated by the Board of Akili as an earn-out service provider prior to the Closing Date (“Earn-Out Service Providers”) received the contingent right to receive additional Common Stock upon the achievement of certain earn-out targets (the “Rights”). The Company concluded the issuance of Rights to Earn-Out Shareholders constitutes a deemed dividend and evaluated the Rights for classification under guidance applicable to financial instruments. In assessing classification, the Company considered ASC Subtopic 815-40 “Contracts in Entity’s Own Equity” and determined the Rights contain settlement provisions that preclude them from being indexed to the Company’s stock and accordingly liability classification is required. The Company concluded issuance of the Rights to Earn-Out Service Providers represents compensation in scope of ASC Topic 718, “Compensation - Stock Compensation.” In considering relevant classification guidance, the Company determined the Rights issued to Earn-Out Service Providers are liabilities because they are indexed to whether such Earn-Out Service Providers hold qualifying equity instruments when the earn-out targets are achieved. The fair value of the contingent earn-out consideration is estimated as of the Closing Date at the present value of the expected contingent earn-out consideration using a Monte Carlo Simulation Method (“MCSM”). The Company reviews the probability of achievement of the earn-out targets to determine the impact on the fair value of the earn-out consideration on a quarterly basis over the earn-out period. For Earn-Out Shareholders, the corresponding fair value was initially recorded against additional paid-in capital. Changes in the estimated fair value of the contingent earn-out consideration related to Earn-Out Shareholders are recorded in other income (expense) in the Consolidated Statements of Operations and Comprehensive Loss and are reflected in the period in which they are identified. For Earn-Out Service Providers, the corresponding fair value was initially recorded within operating expenses in the same functional category as the grantees' operating expenses. Changes in the estimated fair value of contingent earn-out consideration related to Earn-Out Service Providers is recorded as stock compensation for the period. Changes in the estimated fair value of the contingent earn-out consideration may materially impact or cause volatility in the Company's operating results.
Transaction Costs	Transaction Costs: As part of the Business Combination, the Company allocated certain transaction costs to the Earn-out Shares based on the relative fair value of these instruments as compared to the other newly issued instruments. The portion of transaction costs allocated to these instruments was reflected as a reduction to cash and an increase in selling, general and administrative expense. The costs were determined to relate to future share issuances and not to the initial recapitalization and therefore they were expensed on the Closing Date. All costs allocated to the other newly issued instruments, which consisted of Common Stock, were recorded in total permanent equity as a reduction of additional paid-in capital.
Revenue	Revenue: The Company accounts for revenue recognition in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company generates revenue from contracts with caregivers and patients who purchase subscriptions to access EndeavorRx (“Clients”), the Company’s FDA-authorized video game treatment. Clients are billed in advance for the entire subscription term (new subscriptions are currently for 30 days). Along with the subscription to the video game product, Clients also receive reporting metrics and technical support services. The reporting metrics rely on gameplay data being sent back from EndeavorRx, which the Company analyzes in order to provide information on daily efforts and level completion to Clients throughout the subscription term via the EndeavorRx Insight app. The subscription to the video game product, reporting metrics and technical support services are combined as a single stand-ready performance obligation because while the components are separate performance obligations, they have the same method and pattern of recognition. Accordingly, the consideration is recognized ratably on an over time basis over the subscription period which begins once the access code is inputted into the game by the Client and game play has started. In June 2023, the Company released its EndeavorOTC over-the-counter product under the FDA’s COVID-19 Guidance. The Company generates revenue from customers who purchase subscriptions of variable term lengths (currently available as either one month or one year ) to access the video game treatment. Customers are billed in advance for the entire applicable subscription term. Along with the subscription to the video game treatment, the customers also receive technical support services and access to software updates. The technical support services and access to software updates were determined to be immaterial in the context of the contract primarily due to the fact that the underlying selective stimulus management engine (“SSME”) technology is not being updated throughout the subscription term, and therefore the primary functionality of the product is not changed during the term of the arrangement. As EndeavorOTC has significant stand-alone functionality that can be used immediately upon delivery, the performance obligation is considered complete upon delivery and all of the consideration is recognized at that point in time. The Company has generated revenue from a collaboration agreement with Shionogi. The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations that consist of licenses and other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company has determined that the licenses and other promises under the Collaboration Agreement are a single combined performance obligation satisfied over time. The Company must select a single measure of progress that best depicts the Company’s measurement of progress. ASC 606-10-26-33 states that appropriate methods of measuring progress include output methods and input methods and notes that an entity should consider the nature of the good or service that the entity promised to transfer to the customer in determining the appropriate method for measuring progress. Since activities performed to research and validate one phase may be useful in researching and validating subsequent phases, the Company believes that an input method, which tracks the Company’s efforts required to perform the contracted activities during the contract term, is more representationally faithful than an output method, which might track the agreed upon deliverables that are not similar to one another. If an arrangement includes development and regulatory milestone payments or royalties, the Company evaluates whether the milestones or royalties are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone or royalty value is included in the transaction price. Payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The following table presents the Company’s revenue by product type: Year Ended 2023 2022 EndeavorOTC revenue $ 1,155 $ — EndeavorRx revenue 523 323 Total $ 1,678 $ 323 There was no collaboration revenue in either period. As of December 31, 2023, the Company has a contract liability related to EndeavorRx product revenue, which consists of amounts that have been paid but have not been recognized as revenue. All amounts are expected to be recognized as revenue within 12 months of the balance sheet date and are classified as current deferred revenue. The Company recognized $ 106 of product revenue in the year ended December 31, 2023 that was previously included in the December 31, 2022 deferred revenue balance. Contract Liabilities Product Balance at December 31, 2022 $ 106 Revenue recognized 523 Revenue deferred ( 529 ) Balance at December 31, 2023 $ 100
Cost of revenue	Cost of revenue: Cost of revenue includes personnel and related costs, third party contractor expenses, customer support costs, royalties, amortization of capitalized software related to our two commercialized products and software subscriptions related to our products and hosting fees. Sales of EndeavorRx incurred third-party pharmacy dispense fees and sales of EndeavorOTC incur Apple App Store and Google Play fees, both of which are included in cost of revenue. As the Company controls the product until it is transferred to the customer, it is considered the principal in the arrangement and all revenue and cost of revenue is shown gross in the Consolidated Statements of Operations and Comprehensive Loss.
Research and development costs	Research and development costs: Research and development costs are expensed as incurred. Research and development costs include personnel and related costs, consulting costs, external contract research and development expenses, as well as depreciation and utilities. The Company has several agreements with non-related entities to conduct research on behalf of the Company. The expenses incurred associated with these agreements are expensed as incurred within research and development costs.
Advertising	Advertising: The Company expenses advertising costs as incurred. Advertising expenses were $ 6,580 and $ 7,861 during the years ended December 31, 2023 and 2022 .
Accounting for stock-based compensation	Accounting for stock-based compensation: Stock-based compensation made to employees and non-employees, including stock options, restricted stock units (“RSUs”) and performance stock units with market conditions (“PSUs”), is measured based on the grant date fair value of the awards and is recognized as compensation expense typically on a straight-line basis over the period during which the share-based award holder is required to perform services in exchange for the award (the vesting period) for stock options and RSUs and on an accelerated attribution basis for each vesting tranche over the respective derived service period for PSUs. The Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified. The Company recognizes adjustments to stock compensation expense for forfeitures as they occur. The fair value of each stock option grant is estimated on the date of grant using the Black- Scholes option-pricing model. RSUs are measured based on the fair values of the underlying stock on the date of grant. We use the MCSM to estimate the fair value of PSUs. See Note 12 for further discussion of stock-based compensation.
Income taxes	Income taxes: Deferred tax assets and liabilities are recognized based on temporary differences between the financial reporting and income tax basis of assets and liabilities using rates anticipated to be in effect when such temporary differences reverse. A change in tax rates is recognized in income in the period of the enactment date. A valuation allowance against net deferred tax assets is required if, based upon the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company also assesses the probability that the positions taken or expected to be taken in its income tax returns will be sustained by taxing authorities. A “more likely than not” (more than 50%) recognition threshold must be met before a tax benefit can be recognized. Tax positions that are more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position, are reflected in the Company’s consolidated financial statements. Tax positions are measured as the largest amount of tax benefit that is greater than 50 % likely of being realized upon settlement with a taxing authority that has full knowledge of all relevant information. The difference between the benefit recognized for a position and the tax benefit claimed on a tax return is referred to as an unrecognized tax benefit. Potential interest and penalties associated with such uncertain tax positions are recorded as a component of income tax expense.
Comprehensive Loss	Comprehensive Loss: Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders.
Net Loss Per Share	Net Loss Per Share: The Company follows the two-class method when computing net loss per share, or EPS, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.
Segment and Geographic Information	Segment and Geographic Information: Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer, or CEO. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Emerging Growth Company Status	Emerging Growth Company Status: The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company, or EGC, such as Akili to take advantage of an extended transition period to comply with the new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected to use this extended transition period under the JOBS Act until such time the Company is no longer considered to be an EGC, which means that when a standard is issued or revised, it has different applications for public or private companies, the Company will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elect to “opt-out” of such extended transition period or (ii) no longer qualify as an EGC.
Recently Adopted Accounting Pronouncements	Recently adopted accounting pronouncements: In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), as amended by ASU 2019-10. ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. ASU 2016-13 is effective for the Company for the annual reporting period beginning January 1, 2023 . The Company adopted this guidance for the year ended December 31, 2023, however there was no impact to the financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of estimated useful lives of property and equipment	Furniture and fixtures 5 - 7 years Computer equipment and software 3 years Office equipment 3 years Leasehold improvements 3 - 7 years ( Or remaining term of the lease, if shorter ) Internal-use software 2 - 5 years
Summary of Product Type Information	The following table presents the Company’s revenue by product type: Year Ended 2023 2022 EndeavorOTC revenue $ 1,155 $ — EndeavorRx revenue 523 323 Total $ 1,678 $ 323
Summary of Contract Liabilities	Contract Liabilities Product Balance at December 31, 2022 $ 106 Revenue recognized 523 Revenue deferred ( 529 ) Balance at December 31, 2023 $ 100

Business Combination (Tables)

Business Combination (Tables)	12 Months Ended
	Dec. 31, 2023
Business Combinations [Abstract]
Schedule of Reconciles the Elements of Business Combination to Consolidated Statement of Cash Flows and Consolidated Statement of Changes in Equity	The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of changes in equity: Year ended December 31, 2022 Cash - SCS trust and cash (net of redemptions) $ 2,283 Cash - PIPE investors 162,000 Gross proceeds 164,283 Transaction related expenses and other costs paid at Closing (of which $ 8,850 represent the Company's transaction costs) ( 30,989 ) Transaction related expenses and other costs paid after Closing ( 449 ) Net proceeds from the Business Combination 132,845
Schedule of Number of Shares of Common Stock Outstanding Immediately Following Closing	The number of shares of Common Stock outstanding immediately following the Closing was as follows: Common Stock SCS public stockholders 227,522 SCS sponsor and independent director 6,890,000 Legacy Akili stockholders (1) 54,541,224 PIPE investors 16,200,000 Total shares of Common Stock immediately after Closing 77,858,746 (1) The number of Legacy Akili shares was determined from the shares of Legacy Akili shares outstanding immediately prior to the Closing converted at the Exchange Ratio of approximately 1.15 . The amount includes the cashless exercise of certain outstanding Akili Interactive Labs, Inc. warrants, which resulted in the issuance of 8,834 shares of Common Stock. All fractional shares were rounded down. Amount excludes the issuance of 7,536,461 Earn-Out Shares (as defined below), as the performance conditions have not yet been satisfied.
Schedule of Change in Fair Value Recorded as Stock Compensation	The change in fair value is recorded as stock compensation for the period in the same functional category as the grantees' operating expenses. Earn-Out Shareholders Earn-Out Service Providers Total Fair value as of December 31, 2022 $ 4,778 $ 735 $ 5,513 Change in fair value ( 3,363 ) ( 518 ) ( 3,881 ) Fair value as of December 31, 2023 $ 1,415 $ 217 $ 1,632

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Prepaid Expense, Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: December 31, 2023 2022 Prepaid insurance $ 1,008 $ 1,892 Prepaid clinical trials - 697 Other current assets 1,267 1,976 Prepaid expenses and other current assets $ 2,275 $ 4,565

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following: December 31, 2023 2022 Furniture and fixtures $ 116 $ 184 Computer equipment and software 269 477 Office equipment 44 60 Leasehold improvements 885 975 Capitalized internal-use software costs 551 427 Total property and equipment 1,865 2,123 Less: accumulated depreciation and amortization ( 1,185 ) ( 1,204 ) Property and equipment, net $ 680 $ 919

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Future Lease Payments for Noncancelable Operating Leases	Future lease payments for our noncancelable operating leases (excluding short-term leases) as of December 31, 2023 and a reconciliation to the carrying amount of the operating lease liability presented in the consolidated balance sheet as of December 31, 2023 is as follows: Years Ending December 31, Amounts 2024 $ 914 2025 950 2026 904 Total undiscounted payments due under operating leases 2,768 Less imputed interest ( 282 ) Total $ 2,486 Current operating lease liability $ 756 Non-current operating lease liability 1,730 Total $ 2,486

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: December 31, 2023 2022 Accrued bonus $ 2,355 $ 2,819 Accrued royalties 150 110 Accrued wages and benefits 200 1,281 Accrued clinical study expenses 12 292 Accrued consulting service expenses 129 401 Other accrued expenses 480 713 Total $ 3,326 $ 5,616

Corporate Bond (Tables)

Corporate Bond (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Carrying Amount of Corporate Bond	The carrying amount of the corporate bond is as follows: 2023 2022 Corporate Bond $ 5,000 $ 5,000 Unamortized discount on Corporate Bond ( 2,946 ) ( 3,166 ) Corporate Bond, net of discount $ 2,054 $ 1,834

Note Payable (Table)

Note Payable (Table)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Carrying Amount of Note Payable	At December 31, 2023, the carrying amount of the note payable (excluding the current portion of $ 7,500 ) is as follows: Outstanding principal $ 10,625 Note payable, short term ( 7,500 ) Final payment 750 Unamortized debt issuance costs ( 430 ) Note payable, long term (net of debt issuance costs) $ 3,445
Future Minimum Principal Payments Due	Future minimum principal payments due under the Amended and Restated Loan and Security Agreement, excluding the Final Payment, are as follows: Years Ending December 31, 2024 $ 7,500 2025 3,125 Total $ 10,625

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2023
Capital Unit [Line Items]
Summary of Fair Value Of Warrants	The fair value of all option activity was estimated at the date of grant using a Black-Scholes model with the following weighted-average assumptions for the years ended December 31, 2023 and 2022: Year Ended 2023 2022 Fair value of Common Stock $ 0.86 $ 5.03 Expected volatility 104.32 % 99.19 % Expected term (in years) 5.92 5.93 Risk-free interest rate 4.10 % 3.34 % Expected dividend yield 0.00 % 0.00 %
Loan and Security Agreement Warrants
Capital Unit [Line Items]
Summary of Fair Value Of Warrants	The Company determined the fair value of the warrants using the Black-Scholes option model with the following assumptions: Amended and Restated Loan and Security Agreement Warrants May 2021 June 2022 Fair value of common stock $ 3.82 $ 10.06 Expected volatility 95.00 % 96.56 % Expected term (in years) 10.00 8.91 Risk-free interest rate 1.56 % 3.23 % Expected dividend yield 0.00 % 0.00 %

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Summary of Share-Based Compensation Expense	the expense related to Earn-Out Service Providers, is classified in the consolidated statements of operations and comprehensive loss as follows: Year Ended 2023 2022 Research and development $ 2,526 $ 3,493 Selling, general and administrative 4,281 5,816 Total $ 6,807 $ 9,309
Summary of Stock Option Activity and Related Information	Number of Weighted- Weighted- Aggregate Balance at December 31, 2022 12,190,970 $ 3.98 7.36 Granted 5,199,280 $ 0.86 Cancelled ( 2,769,719 ) $ 3.58 Exercised ( 28,778 ) $ 0.03 Balance at December 31, 2023 14,591,753 $ 2.94 7.31 $ 285 Exercisable December 31, 2023 7,593,913 $ 3.71 5.53 $ 99 Options vested and expected to vest, December 31, 2023 14,591,753 $ 2.94 7.31 $ 285
Summary of Stock Option Activity Weighted-Average Assumptions	The fair value of all option activity was estimated at the date of grant using a Black-Scholes model with the following weighted-average assumptions for the years ended December 31, 2023 and 2022: Year Ended 2023 2022 Fair value of Common Stock $ 0.86 $ 5.03 Expected volatility 104.32 % 99.19 % Expected term (in years) 5.92 5.93 Risk-free interest rate 4.10 % 3.34 % Expected dividend yield 0.00 % 0.00 %
Summary of RSUs Activity	The following table summarizes RSU activity for the year ended December 31, 2023: Number of Weighted- Balance at December 31, 2022 801,401 $ 2.30 Granted 3,121,125 $ 0.82 Vested ( 321,739 ) $ 2.08 Forfeited ( 601,950 ) $ 1.74 Balance at December 31, 2023 2,998,837 $ 0.89
Summary of PSUs activity	The following table summarizes PSU activity for the year ended December 31, 2023: Number of Weighted- Balance at December 31, 2022 4,554,408 $ 1.50 Granted — n/a Vested — n/a Forfeited ( 2,526,274 ) $ 1.50 Balance at December 31, 2023 2,028,134 $ 1.50

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values: Fair Value Measurements as of December 31, 2023 Description Level 1 Level 2 Level 3 Total Assets Cash equivalents: Money market funds $ 61,539 $ - $ - $ 61,539 Liabilities Long-term liabilities: Earn-out liabilities $ - $ - $ 1,632 $ 1,632 Fair Value Measurements as of December 31, 2022 Description Level 1 Level 2 Level 3 Total Assets Cash equivalents: Money market funds $ 32,829 $ - $ - $ 32,829 Short-term investments: United States treasuries 82,034 - - 82,034 Total assets $ 114,863 $ - $ - $ 114,863 Liabilities Long-term liabilities: Earn-out liabilities - - 5,513 5,513 Total liabilities $ - $ - $ 5,513 $ 5,513

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Components of Provision For Income Taxes	The provision for income taxes consists of the following components: Years Ended December 31, 2023 2022 Current Federal $ — $ — State 53 19 Total current expense (benefit) 53 19 Deferred Federal - - State - - Total deferred expense (benefit) $ — $ — Total tax recognized $ 53 $ 19
Schedule of Effective Income Tax Rate Reconciliations	A reconciliation setting forth the differences between effective tax rate of the Company as well as the U.S. federal statutory tax rate is as follows: Years Ended December 31, 2023 2022 Benefit at federal statutory rate 21.00 % 21.00 % State taxes 4.73 % 54.48 % Credits 1.38 % 13.63 % Transaction costs 0.00 % ( 6.22 %) Gain on earn-out shares 1.19 % 218.69 % Share-based payment measurement ( 0.78 %) ( 10.45 %) Other ( 0.10 %) 2.56 % Change in valuation allowance ( 27.51 %) ( 293.93 %) Effective tax rate ( 0.09 %) ( 0.24 %)
Schedule of Components of Deferred Tax Assets And Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows: Years Ended December 31, 2023 2022 Deferred tax assets: Operating tax losses $ 67,464 $ 55,350 Research credits 8,586 7,416 Temporary differences 1,240 1,337 Research and development costs 6,799 4,823 Start-up costs 2,075 2,197 Lease liability 617 847 Share based payments 4,484 3,298 Gross deferred tax assets 91,265 75,268 Valuation Allowance ( 90,364 ) ( 74,010 ) Deferred tax assets, Less: valuation allowance 901 1,258 Deferred tax liabilities: Right-of-use asset ( 391 ) ( 664 ) Other temporary differences ( 510 ) ( 594 ) Deferred tax liabilities ( 901 ) ( 1,258 ) Total $ — $ —

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: Year Ended 2023 2022 Numerator: Net loss $ ( 59,493 ) $ ( 7,964 ) Dividends on Series D convertible preferred stock - ( 7,383 ) Redemption value of Series D convertible preferred stock - ( 3,692 ) Net loss attributable to common stockholders - basic and diluted $ ( 59,493 ) $ ( 19,039 ) Denominator: Weighted average common stock outstanding 78,197,107 29,878,041 Net loss per share attributable to common stockholders - basic and diluted $ ( 0.76 ) $ ( 0.64 )
Summary of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders Including Anti-dilutive Effect	The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: Year Ended 2023 2022 Warrants to purchase Common Stock 133,578 242,924 Stock options to purchase Common Stock 14,591,753 12,190,970 Earn-out shares 7,536,461 7,536,461 Unvested RSUs 2,998,837 801,401 Unvested PSUs 2,028,134 4,554,408 Total 27,288,763 25,326,164

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) Segment $ / shares shares	Dec. 31, 2022 USD ($) $ / shares	Aug. 19, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Lite Items]
Number of business segments | Segment	1
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001
Cash and cash equivalents and short term investments	$ 75,150
Accumulated deficit	$ (299,781)	$ (240,288)
SCS
Organization, Consolidation and Presentation of Financial Statements [Lite Items]
Business combination, issuance of common shares | shares	16,200,000
Common stock, par value | $ / shares	$ 0.0001
Business acquisition share price | $ / shares	$ 10
Business combination amount	$ 162,000
Business combination merger included funds in trust account	164,283
Business combination, transaction costs	$ 31,438	$ 12,927	$ 31,438
Business combination exchange ratio	1.15%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue, revenue recognized		$ 523,000
Advertising Expense		$ 6,580,000	$ 7,861,000
Lease term description		Leases with terms greater than one-year are recognized on the consolidated balance sheets as right-of-use assets and lease liabilities and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates or abatements we expect to receive from the lessor.
Lease, option to extend		Options to extend a lease are included in the expected lease term if exercise of the option is deemed reasonably certain.
Minimum percentage of tax benefit amount to measure tax positions realized upon settlement		50%
Impairment loss		$ 385,000
Write-down in right-of-use asset		$ 1,577,000	2,596,000
Subscriptions term		30 days
Revenues		$ 1,678,000	$ 323,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Subscriptions term	1 month
Maximum
Summary Of Significant Accounting Policies [Line Items]
Subscriptions term	1 year
Sublease Agreement
Summary Of Significant Accounting Policies [Line Items]
Impairment loss		384,000
Write-down in right-of-use asset		325,000
Leasehold improvements		$ 59,000
Significant Customer | Customer concentration risk | Revenue
Summary Of Significant Accounting Policies [Line Items]
Significant concentration		0%	0%
ASU 2016-13
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adoption date		Jan. 01, 2023
Change in accounting principle, accounting standards update, adopted		true
Change in accounting principle, accounting standards update, immaterial effect		true
Product Revenue
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue, revenue recognized		$ 106,000
Collaboration Revenue
Summary Of Significant Accounting Policies [Line Items]
Revenues		$ 0	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of estimated useful lives of property and equipment (Details)	Dec. 31, 2023
Furniture and Fixtures | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	5 years
Furniture and Fixtures | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	7 years
Computer equipment and software
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	3 years
Office Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	3 years
Leasehold Improvements
Summary Of Significant Accounting Policies [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember
Leasehold Improvements | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	3 years
Leasehold Improvements | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	7 years
Internal-use software | Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	2 years
Internal-use software | Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Product Type Information (Details) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Summary Of Significant Accounting Policies [Line Items]
Revenues	$ 1,678,000	$ 323,000
EndeavorOTC revenue
Summary Of Significant Accounting Policies [Line Items]
Revenues	1,155,000	0
EndeavorRx revenue
Summary Of Significant Accounting Policies [Line Items]
Revenues	$ 523,000	$ 323,000

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Contract Liabilities (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Accounting Policies [Abstract]
Beginning balance	$ 106
Revenue recognized	523
Revenue deferred	(529)
Ending balance	$ 100

Business Combination - Addition

Business Combination - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Aug. 19, 2022	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Earn-out shares, share price		$ 0.49
SCS
Business Acquisition [Line Items]
Business combination, common stock exchange ratio	1.15%
Business combination, transaction related expenses and other costs	$ 31,438	$ 31,438	$ 12,927
Business combination transaction cost paid			8,850
Business combination additional transaction costs paid			$ 4,077
SCS | Common Stock
Business Acquisition [Line Items]
Business combination, earn-out shares		7,536,461
Trading days		20 days
Consecutive trading day period		30 days
SCS | Common Stock | Tranche One
Business Acquisition [Line Items]
Earn-out shares, share price		$ 15
SCS | Common Stock | Tranche Two
Business Acquisition [Line Items]
Earn-out shares, share price		20
SCS | Common Stock | Tranche Three
Business Acquisition [Line Items]
Earn-out shares, share price		$ 30
SCS | Earn-out shares
Business Acquisition [Line Items]
Business combination, transaction related expenses and other costs	$ 3,046

Business Combination - Schedule

Business Combination - Schedule of Reconciles the Elements of Business Combination to Consolidated Statement of Cash Flows and Consolidated Statement of Changes in Equity (Details) - SCS $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Gross proceeds	$ 164,283
Transaction related expenses and other costs paid at Closing (of which $8,850 represent the Company's transaction costs)	30,989
Transaction related expenses and other costs paid after Closing	(449)
Net proceeds from the Business Combination	132,845
PIPE Investors
Business Acquisition [Line Items]
Gross proceeds	162,000
SCS Trust and Cash (Net of Redemptions)
Business Acquisition [Line Items]
Gross proceeds	$ 2,283

Business Combination - Schedu_2

Business Combination - Schedule of Reconciles the Elements of Business Combination to Consolidated Statement of Cash Flows and Consolidated Statement of Changes in Equity (Parenthetical) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
SCS
Business Acquisition [Line Items]
Business combination transaction cost paid	$ 8,850

Business Combination - Schedu_3

Business Combination - Schedule of Number of Shares of Common Stock Outstanding Immediately Following Closing (Details) - shares	Dec. 31, 2023	Dec. 31, 2022	Aug. 19, 2022
Business Acquisition [Line Items]
Common stock, shares outstanding	78,356,527	78,022,924
SCS
Business Acquisition [Line Items]
Common stock, shares outstanding			77,858,746
SCS | SCS Public Stockholders
Business Acquisition [Line Items]
Common stock, shares outstanding			227,522
SCS | SCS Sponsor and Independent Director
Business Acquisition [Line Items]
Common stock, shares outstanding			6,890,000
SCS | Legacy Akili stockholders
Business Acquisition [Line Items]
Common stock, shares outstanding			54,541,224
SCS | PIPE Investors
Business Acquisition [Line Items]
Common stock, shares outstanding			16,200,000

Business Combination - Schedu_4

Business Combination - Schedule of Number of Shares of Common Stock Outstanding Immediately Following Closing (Parenthetical) (Details) - shares			12 Months Ended
	Aug. 19, 2022	Aug. 18, 2022	Dec. 31, 2023
SCS
Business Acquisition [Line Items]
Business combination, common stock exchange ratio	1.15%
Business combination, issuance of common shares			16,200,000
Legacy Akili stockholders
Business Acquisition [Line Items]
Business combination, common stock exchange ratio	1.15%	1.15%
Business combination, earn-out shares	7,536,461
Legacy Akili stockholders | SCS
Business Acquisition [Line Items]
Business combination, issuance of common shares	8,834

Business Combination - Schedu_5

Business Combination - Schedule of Change in Fair Value Recorded as Stock Compensation (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Business Acquisition [Line Items]
Fair value as of December 31, 2022	$ 5,513
Change in fair value	(3,881)
Fair value as of December 31, 2023	1,632
Earn-Out Shareholders
Business Acquisition [Line Items]
Fair value as of December 31, 2022	4,778
Change in fair value	(3,363)
Fair value as of December 31, 2023	1,415
Earn-Out Service Providers
Business Acquisition [Line Items]
Fair value as of December 31, 2022	735
Change in fair value	(518)
Fair value as of December 31, 2023	$ 217

Option and Collaboration Agre_2

Option and Collaboration Agreements (Additional Information) (Details) - USD ($) $ in Thousands		1 Months Ended		12 Months Ended
	Dec. 19, 2018	Oct. 31, 2019	Mar. 31, 2019	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Option And Collaboration Agreements [Line Items]
Corporate bond				$ 5,000	$ 5,000
Option And Collaboration Agreement [Member] | Shinogi And Company Limited [Member]
Option And Collaboration Agreements [Line Items]
Upfront payment received	$ 10,000
Cash payment received to exercise the option			$ 10,000
Commercial and milestone payments receivable			105,000
Modification in terms of the collaboration agreement fee received		$ 387
Deferred revenue						$ 24,192
Payments for royalties				$ 0	$ 0
Option And Collaboration Agreement [Member] | Shinogi And Company Limited [Member] | Corporate Bond Securities
Option And Collaboration Agreements [Line Items]
Corporate bond			5,000
Initial discount on corporate bond			$ 3,805

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Prepaid Expense, Current [Abstract]
Prepaid insurance	$ 1,008	$ 1,892
Prepaid clinical trials		697
Other current assets	1,267	1,976
Prepaid expenses and other current assets	$ 2,275	$ 4,565

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property and equipment	$ 1,865	$ 2,123
Less: accumulated depreciation and amortization	(1,185)	(1,204)
Property and equipment, net	680	919
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment	116	184
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment	269	477
Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment	44	60
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment	885	975
Capitalized Internal-Use Software Costs
Property Plant And Equipment [Line Items]
Property and equipment	$ 551	$ 427

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 302	$ 308

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Thousands			12 Months Ended
	Nov. 09, 2023 USD ($)	May 31, 2023 USD ($) ft²	Dec. 31, 2023 USD ($) ft²	Dec. 31, 2022 USD ($)
Commitments and Contingencies [Line Items]
Sublease rent expense			$ 757
Rent expense				$ 1,026
Net cash paid for operating lease liability			$ 1,042
Lease term			2 years 10 months 24 days
Operating lease borrowing rate			7.6
Security Deposit | Restricted Cash
Commitments and Contingencies [Line Items]
Letter of credit			$ 250
Massachusetts
Commitments and Contingencies [Line Items]
Lessee area of operating lease | ft²			4,000
Operating lease expiration period			2023-12
Larkspur, California
Commitments and Contingencies [Line Items]
Lessee area of operating lease | ft²			43,600
Operating lease expiration period			2026-11
Larkspur, California | Sublease Agreement
Commitments and Contingencies [Line Items]
Lessee area of operating lease | ft²		5,716
Operating lease commencement date		Jun. 01, 2023
Operating lease expiration period		2026-11
Sublease exchange amount per month		$ 23	$ 74
Sublease increased percentage		4%	4%
Boston Office Space
Commitments and Contingencies [Line Items]
Sum of license fee agreed to pay per month	$ 9
Effective date of new agreement	Jan. 01, 2024
New agreement term	1 year
Renewal term of new agreement	1 year

Commitments and Contingencies_2

Commitments and Contingencies - Future Lease Payments for Noncancelable Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
2024	$ 914
2025	950
2026	904
Total undiscounted payments due under operating leases	2,768
Less imputed interest	(282)
Total	2,486
Current operating lease liability	756	$ 826
Non-current operating lease liability	$ 1,730	$ 2,485

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued bonus	$ 2,355	$ 2,819
Accrued royalties	150	110
Accrued wages and benefits	200	1,281
Accrued clinical study expenses	12	292
Accrued consulting service expenses	129	401
Other accrued expenses	480	713
Total	$ 3,326	$ 5,616

Corporate Bond - Additional Inf

Corporate Bond - Additional Information (Detail) - USD ($)		12 Months Ended
	Mar. 31, 2019	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Corporate bond		$ 5,000,000	$ 5,000,000
Corporate Bond Securities
Debt Instrument [Line Items]
Amortization expense		$ 220,000	$ 196,000
Corporate Bond Securities | Option And Collaboration Agreement
Debt Instrument [Line Items]
Estimated market rate of interest	12%
Maturity date of corporate bond	Nov. 10, 2031
Fixed interest rate	0%
Initial discount on corporate bond	$ 3,805
Corporate Bond Securities | Shinogi And Company Limited | Option And Collaboration Agreement
Debt Instrument [Line Items]
Corporate bond	$ 5,000

Corporate Bond - Schedule Of Su

Corporate Bond - Schedule Of Subordinated Borrowing (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Subordinated Borrowings [Abstract]
Corporate bond	$ 5,000	$ 5,000
Unamortized discount on corporate bond	(2,946)	(3,166)
Corporate bond, net of discount	$ 2,054	$ 1,834

Note Payable - Additional Infor

Note Payable - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Jun. 30, 2022	May 31, 2021	Dec. 31, 2023	Dec. 31, 2022	May 25, 2021
Debt Instrument [Line Items]
Repayment of notes payable			$ 4,375
Warrants outstanding to purchase common stock			133,578
Interest expense, debt			$ 2,358	$ 1,484
Selling, general and administrative expense			$ 45,419	$ 61,701
Interest rate			12.30%	11.30%
Weighted average interest rate			11.90%	9.20%
Note payable, short term			$ 7,500	$ 4,375
Loan and Security Agreement
Debt Instrument [Line Items]
Loan borrowed	$ 10,000	$ 5,000
Debt frequency of payment			24 equal monthly payments
Maturity date of agreement			May 01, 2025
Debt interest rate			7%
Debt issuance costs	782				$ 559
Debt instrument final payment rate			5%
Final Payment	500				$ 250
Issuance of fully-vested warrants to purchase shares of common stock		84,350
Exercise price per share		$ 3.82
Estimated fair value of common warrants issued	$ 282	$ 268
Warrants outstanding to purchase common stock	31,242
Outstanding principal amount			$ 10,625
Interest expense, debt			503	341
Selling, general and administrative expense			$ 42	$ 211
Loan and Security Agreement | Prime Rate
Debt Instrument [Line Items]
Variable interest rate			3.75%
Loan and Security Agreement | Repaid after May 25, 2023
Debt Instrument [Line Items]
Prepayment fee percentage			1%

Note Payable - Schedule of Carr

Note Payable - Schedule of Carrying Amount of Note Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Note payable, short term	$ (7,500)	$ (4,375)
Note payable, long term (net of debt issuance costs)	3,445	$ 10,442
Note Payable
Debt Instrument [Line Items]
Outstanding principal	10,625
Note payable, short term	(7,500)
Final payment	750
Unamortized debt issuance costs	(430)
Note payable, long term (net of debt issuance costs)	$ 3,445

Note Payable - Future Minimum P

Note Payable - Future Minimum Principal Payments Due (Details) - Loan and Security Agreement $ in Thousands	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
2024	$ 7,500
2025	3,125
Outstanding principal	$ 10,625

Capital Stock - Additional Info

Capital Stock - Additional Information (Details) - USD ($)			1 Months Ended		12 Months Ended
	Aug. 19, 2022	Aug. 18, 2022	Jun. 30, 2022	May 31, 2021	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Common stock, shares authorized					1,000,000,000	1,000,000,000
Common stock, par value					$ 0.0001	$ 0.0001
Redeemable convertible preferred stock, shares authorized					100,000,000
Redeemable convertible preferred stock, par value					$ 0.0001
Common stock, shares issued					78,356,527	78,022,924
Common stock, shares outstanding					78,356,527	78,022,924
Warrants outstanding to purchase common stock					133,578
Redeemable convertible preferred stock, shares issued					0
Redeemable convertible preferred stock, shares outstanding					0
Number of vote for each share of common stock					1
Loan and Security Agreement Warrants
Class of Stock [Line Items]
Warrants outstanding to purchase common stock			31,242	224,938
Number of shares vested and exercisable				84,350	17,986
Estimated fair value of common warrants issued			$ 282,000	$ 268,000
Exercise price per share				$ 3.82	$ 5.95
Legacy Akili stockholders
Class of Stock [Line Items]
Business combination, common stock exchange ratio	1.15%	1.15%
2022 Employee Stock Purchase plan
Class of Stock [Line Items]
Common stock, shares issued					0
Percentage of lower of fair market value of stock					85%
Maximum offering period					27 months
Limitation on employee payroll deductions percentage					15%
Employee purchase of stock maximum amount					$ 25,000
Common stock reserved for future issuance					1,167,881
Percentage of outstanding shares issued and outstanding					1%

Capital Stock - Summary of Fair

Capital Stock - Summary of Fair Value Of Warrants (Details) - $ / shares	1 Months Ended		12 Months Ended
	Jun. 30, 2022	May 31, 2021	Dec. 31, 2023	Dec. 31, 2022
Temporary Equity [Line Items]
Fair value of common stock			$ 0.86	$ 5.03
Expected volatility			104.32%	99.19%
Expected term (in years)			5 years 11 months 1 day	5 years 11 months 4 days
Risk-free interest rate			4.10%	3.34%
Expected dividend yield			0%	0%
Loan and Security Agreement Warrants
Temporary Equity [Line Items]
Fair value of common stock	$ 10.06	$ 3.82
Expected volatility	96.56%	95%
Expected term (in years)	8 years 10 months 28 days	10 years
Risk-free interest rate	3.23%	1.56%
Expected dividend yield	0%	0%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Nov. 02, 2022 $ / shares	Dec. 31, 2023 USD ($) Employees $ / shares shares	Dec. 31, 2022 USD ($) $ / shares
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Cash outflows related to the payment of withholding taxes for vested RSUs		$ 118	$ 28
Stock-based compensation		$ 6,807	$ 9,309
Weighted average grant-date fair value of stock options granted to employees | $ / shares		$ 0.7	$ 3.94
Aggregate intrinsic value of stock option awards exercised		$ 40	$ 504
Terminated employees | Employees		69
Incremental compensation expenses		$ 208
Closing stock price | $ / shares		$ 0.49
Risk-free interest rate		4.10%	3.34%
Expected term (in years)		5 years 11 months 1 day	5 years 11 months 4 days
Expected volatility		104.32%	99.19%
Expected dividend yield		0%	0%
Restricted Stock Units (RSUs)
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Cash outflows related to the payment of withholding taxes for vested RSUs		$ 118
Vesting percentage		25%
Unrecognized compensation cost related to unvested stock options/RSUs/PSUs grants to employees		$ 2,435
Unrecognized compensation cost, expected to be recognized over a weighted-average period		2 years 6 months
Stock Options
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Vesting percentage		25%
Expiration period (in years)		10 years
Option vesting period		3 years
Unrecognized compensation cost related to unvested stock options/RSUs/PSUs grants to employees		$ 10,219
Unrecognized compensation cost, expected to be recognized over a weighted-average period		2 years 2 months 12 days
Performance Stock Units (PSUs)
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Option vesting period		5 years
Unrecognized compensation cost related to unvested stock options/RSUs/PSUs grants to employees		$ 1,737
Unrecognized compensation cost, expected to be recognized over a weighted-average period		1 year 7 months 6 days
Number of trading days subject to achievement of specified performance goals		30 days
Closing stock price | $ / shares	$ 2.3
Risk-free interest rate		4.30%
Expected term (in years)		5 years
Expected volatility	95%
Expected dividend yield		0%
Minimum
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Option vesting period		3 months
Maximum
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Option vesting period		2 years
Tranche One | Restricted Stock Units (RSUs)
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Vesting percentage		16.67%
Option vesting period		3 years
Tranche One | Stock Options
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Vesting percentage		25%
Option vesting period		2 years
Tranche Two | Restricted Stock Units (RSUs)
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Vesting percentage		12.50%
Option vesting period		4 years
Tranche Two | Stock Options
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Vesting percentage		16.67%
Option vesting period		3 years
Tranche Three | Restricted Stock Units (RSUs)
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Vesting percentage		25%
Option vesting period		2 years
Tranche Three | Stock Options
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Vesting percentage		12.50%
Option vesting period		4 years
Earn-Out Shares to Earn-Out Service Provider
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Stock-based compensation		$ 518	$ 735
2022 Stock Option and Incentive Plan
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Common stock reserved for future issuance | shares		12,813,781

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 6,807	$ 9,309
Research and Development
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	2,526	3,493
Selling, General and Administrative
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 4,281	$ 5,816

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Number of Options, Beginning Balance	12,190,970
Number of Options, Granted	5,199,280
Number of Options, Cancelled	(2,769,719)
Number of Options, Exercised	(28,778)
Number of Options, Ending Balance	14,591,753	12,190,970
Number of Options, Exercisable	7,593,913
Number of Options, Options Vested and Expected to Vest	14,591,753
Weighted Average Exercise Price Per Share, Beginning Balance	$ 3.98
Weighted Average Exercise Price Per Share, Granted	0.86
Weighted Average Exercise Price Per Share, Cancelled	3.58
Weighted Average Exercise Price Per Share, Exercised	0.03
Weighted Average Exercise Price Per Share, Ending Balance	2.94	$ 3.98
Weighted Average Exercise Price Per Share, Exercisable	3.71
Weighted Average Exercise Price Per Share, Options Vested and Expected to Vest	$ 2.94
Weighted Average Remaining Contractual Term (in Years), Balance	7 years 3 months 21 days	7 years 4 months 9 days
Weighted Average Remaining Contractual Term (in Years), Exercisable	5 years 6 months 10 days
Weighted Average Remaining Contractual Term (in Years), Options vested and expected to vest	7 years 3 months 21 days
Aggregate Intrinsic Value, Balance	$ 285
Aggregate Intrinsic Value, Exercisable	99
Aggregate Intrinsic Value, Options vested and expected to vest	$ 285

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock Option Activity Weighted Average Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Fair value of common stock	$ 0.86	$ 5.03
Expected volatility	104.32%	99.19%
Expected term (in years)	5 years 11 months 1 day	5 years 11 months 4 days
Risk-free interest rate	4.10%	3.34%
Expected dividend yield	0%	0%

Stock-Based Compensation - The

Stock-Based Compensation - The Summary of RSU and PSU Activity (Details)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Restricted Stock Units (RSUs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Beginning Balance | shares	801,401
Granted | shares	3,121,125
Vested | shares	(321,739)
Forfeited | shares	(601,950)
Ending Balance | shares	2,998,837
Beginning Balance, Weighted-Average Grant Date Fair Value | $ / shares	$ 2.3
Granted, Weighted-Average Grant Date Fair Value | $ / shares	0.82
Vested, Weighted-Average Grant Date Fair Value | $ / shares	2.08
Forfeited, Weighted-Average Grant Date Fair Value | $ / shares	1.74
Ending Balance, Weighted-Average Grant Date Fair Value | $ / shares	$ 0.89
Performance Stock Units (PSUs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Beginning Balance | shares	4,554,408
Forfeited | shares	(2,526,274)
Ending Balance | shares	2,028,134
Beginning Balance, Weighted-Average Grant Date Fair Value | $ / shares	$ 1.5
Forfeited, Weighted-Average Grant Date Fair Value | $ / shares	1.5
Ending Balance, Weighted-Average Grant Date Fair Value | $ / shares	$ 1.5

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities - Fair Value of Assets and Liabilities on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets
Short-term investments		$ 82,034
Fair Value, Measurements, Recurring
Assets
Total assets		114,863
Long-term liabilities:
Total liabilities		5,513
Fair Value, Measurements, Recurring | Earn-Out Liabilities
Long-term liabilities:
Total liabilities	$ 1,632	5,513
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1
Assets
Total assets		114,863
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3
Long-term liabilities:
Total liabilities		5,513
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 | Earn-Out Liabilities
Long-term liabilities:
Total liabilities	1,632	5,513
Fair Value, Measurements, Recurring | Money Market Funds
Assets
Cash equivalents	61,539	32,829
Fair Value, Measurements, Recurring | Money Market Funds | Fair Value, Inputs, Level 1
Assets
Cash equivalents	$ 61,539	32,829
Fair Value, Measurements, Recurring | US Treasury Securities
Assets
Short-term investments		82,034
Fair Value, Measurements, Recurring | US Treasury Securities | Fair Value, Inputs, Level 1
Assets
Short-term investments		$ 82,034

Fair Value of Financial Asset_4

Fair Value of Financial Assets and Liabilities - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Fair value, transfers of financial instruments between levels	$ 0	$ 0
Unrealized losses on short-term Investments in other comprehensive loss	$ 21,000	(21,000)
Earn-out shares, share price	$ 0.49
Earn-out shares, expected term	3 years 7 months 6 days
Earn-out shares, expected volatility rate	119.50%
Earn-out shares, expected dividend yield	0%
Triggering Event I
Business Acquisition [Line Items]
Earn-out shares, share price	$ 15
Triggering Event II
Business Acquisition [Line Items]
Earn-out shares, share price	20
Triggering Event III
Business Acquisition [Line Items]
Earn-out shares, share price	$ 30
Fair Value, Measurements, Recurring
Business Acquisition [Line Items]
Liabilities, fair value		$ 5,513,000
Short-Term Investments | US Treasury Securities | Maximum
Business Acquisition [Line Items]
Original maturities term of investments from date of purchase	1 year	1 year
Short-Term Investments | US Treasury Securities | Minimum
Business Acquisition [Line Items]
Original maturities term of investments from date of purchase	3 months	3 months
Cash And Cash Equivalents | Money Market Funds | Maximum
Business Acquisition [Line Items]
Original maturities term of investments from date of purchase	90 days	90 days

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Current
Federal	$ 0	$ 0
State	53	19
Total current expense (benefit)	53	19
Deferred
Federal	0	0
State	0	0
Total deferred expense (benefit)	0	0
Total tax recognized	$ 53	$ 19

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliations (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Benefit at federal statutory rate	21%	21%
State taxes	4.73%	54.48%
Credits	1.38%	13.63%
Transaction costs	0%	(6.22%)
Gain on earn-out shares	1.19%	218.69%
Share-based payment measurement	(0.78%)	(10.45%)
Other	(0.10%)	2.56%
Change in valuation allowance	(27.51%)	(293.93%)
Effective tax rate	(0.09%)	(0.24%)

Income Taxes - Schedule of Co_2

Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Operating tax losses	$ 67,464	$ 55,350
Research credits	8,586	7,416
Temporary differences	1,240	1,337
Research and development costs	6,799	4,823
Start-up costs	2,075	2,197
Lease liability	617	847
Share based payments	4,484	3,298
Gross deferred tax assets	91,265	75,268
Valuation Allowance	(90,364)	(74,010)
Deferred tax assets, Less: valuation allowance	901	1,258
Deferred tax liabilities:
Right-of-use asset	(391)	(664)
Other temporary differences	(510)	(594)
Deferred tax liabilities	$ (901)	$ (1,258)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Contingency [Line Items]
Deferred tax assets operating loss carryforwards	$ 275,482,000
Deferred tax assets operating loss carryforwards subject to expiration	31,208,000
Deferred tax assets operating loss carryforwards not subject to expiration	244,274,000
Deferred tax assets operating loss carryforwards state	162,969,000
Net change in the valuation allowance	16,354,000	$ 27,723,000
Capitalized research and development expenses	13,906,000	20,859,000
Unrecognized tax benefits	$ 0	$ 0
U.S.
Income Tax Contingency [Line Items]
Amortized research and development expenses period		5 years
Outside U.S.
Income Tax Contingency [Line Items]
Amortized research and development expenses period		15 years
Reserach and Development tax credit carryforward
Income Tax Contingency [Line Items]
Net operating loss carryforwards expiration year	2039
Federal
Income Tax Contingency [Line Items]
Deferred tax assets tax credits carryforwards	$ 6,330,000
Net operating loss carryforwards expiration year	2031
State
Income Tax Contingency [Line Items]
Deferred tax assets tax credits carryforwards	$ 2,856,000
Net operating loss carryforwards expiration year	2031
State | Reserach and Development tax credit carryforward
Income Tax Contingency [Line Items]
Net operating loss carryforwards expiration year	2033

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Numerator:
Net loss	$ (59,493)	$ (7,964)
Dividends on Series D convertible preferred stock	0	(7,383)
Redemption value of Series D convertible preferred stock	0	(3,692)
Net loss attributable to common stockholders - basic	(59,493)	(19,039)
Net loss attributable to common stockholders - diluted	$ (59,493)	$ (19,039)
Denominator:
Weighted average common shares outstanding, Basic	78,197,107	29,878,041
Weighted average common shares outstanding - diluted	78,197,107	29,878,041
Net loss per share attributable to common stockholders - basic	$ (0.76)	$ (0.64)
Net loss per share attributable to common stockholders - diluted	$ (0.76)	$ (0.64)

Net Loss Per Share - Summary _2

Net Loss Per Share - Summary of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders Including Anti-dilutive Effect (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	27,288,763	25,326,164
Warrants to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	133,578	242,924
Stock Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	14,591,753	12,190,970
Earn-out shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	7,536,461	7,536,461
Unvested RSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	2,998,837	801,401
Unvested PSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	2,028,134	4,554,408

Employee Benefit Plan (Addition

Employee Benefit Plan (Additional Information) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Postemployment Retirement Benefits [Member]
Defined Contribution Plan Disclosure [Line Items]
Defined contribution plan, employer contribution	$ 689	$ 784

Restructuring Charges - Additio

Restructuring Charges - Additional Information (Details) $ in Thousands			12 Months Ended
	Sep. 13, 2023	Jan. 12, 2023	Dec. 31, 2023 USD ($) Employees
Accrued Expenses and Other Current Liabilities
Restructuring Cost and Reserve [Line Items]
Unpaid restructuring expenses			$ 94
Pipeline Programs
Restructuring Cost and Reserve [Line Items]
Restructuring operations announcement date		Jan. 12, 2023
Restructuring charge			$ 2,329
Number of employees related to restructuring | Employees			48
Percentage of employee base at time of restructuring			31%
Field Sales Force
Restructuring Cost and Reserve [Line Items]
Restructuring operations announcement date	Sep. 13, 2023
Restructuring charge			$ 2,401
Number of employees related to restructuring | Employees			47
Percentage of employee base at time of restructuring			40%